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Abstract 
Amyloid fibrils, a major pathological feature of several neurodegenerative disorders, 
are highly stable, insoluble aggregates of misfolded proteins. The formation of such 
aggregates involves a complex equilibrium between protein monomers, different on- 
and off-pathway transient oligomeric species, and amyloid fibrils. Amyloid fibril 
formation in vivo may be induced by a myriad of factors, including oxidative stress and 
alteration of metal ion homeostasis.  
The work in this thesis involves biophysical studies of the amyloid fibril formation 
mechanisms of the natively folded Ca2+-binding fish protein, β-parvalbumin (β-PV); and 
how it is modulated by cell conditions including macromolecular crowding and 
stabilizing osmolytes, both of which tend to stabilize compact folded protein 
conformations through an excluded volume- or osmophobic effect, respectively. It was 
found that when β-PV aggregation is triggered, as occurs upon Ca2+ removal from the 
protein, spontaneous cystine formation between β-PV monomers initiates the process, 
whereafter the dimers template monomers into the amyloid conformation, resulting in 
polymerization. Furthermore, it was discovered that both excluded volume and the 
osmophobic effect promote the overall aggregation of β-PV, likely by facilitating protein 
dimerization. Together, these results highlight the potentially detrimental effects of 
ligand loss and oxidative stress on proteins, whose destabilization might induce 
amyloid fibril formation that is further exacerbated by otherwise protective in-cell 
conditions. 
Amyloid fibril formation by fish β-PV at acidic pH is thought to confer protection 
against proteolytic degradation in the human gut. In addition, since recent evidence 
suggests that many incidences of the neurodegenerative disorder Parkinson’s disease 
(PD) might originate from the gut, a putative interaction between β-PV and α-synuclein 
(αS), which forms amyloid fibrils in PD, was tested in vitro. Amyloid fibrils of β-PV block 
αS aggregation, likely by sequestering αS monomers onto the surface, thus potentially 
implying a protective effect of a diet rich in fish against PD. Lastly, in light of the fact 
that copper is reduced in affected brain regions of PD patients, as well as the presence 
of copper binding sites on αS, aggregation of αS in the presence of the endogenous 
cytoplasmic copper chaperone, Atox1, was studied. It was found that copper-Atox1 
interacts with αS and can prevent its aggregation, while apo-Atox1 is ineffective, 
indicating a copper dependent interaction. The reduced copper levels associated with 
PD might thus play a role in PD progression by abolishing this protective interaction. 
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Prior to the emergence of the germ theory of disease, which resulted in improved public 
health and hygiene, as well as the invention of vaccines and antibiotics, infections were 
the biggest challenge to human health (1). However, with the epidemiological transition 
after the industrial revolution, together with medical advances, followed an increasing 
number of chronic, noncommunicable and recurrent diseases, e.g. cancer and 
neurodegenerative diseases (1). Neurodegenerative diseases pose a major burden on 
the well-being of the afflicted, their family and friends, and both private and national 
economy, with the latter being expected to increase nearly five-fold from 2016 to 2050 
for dementia related diseases alone (2). A common thread among many 
neurodegenerative diseases is the appearance of highly stable protein deposits known 
as amyloids that occurs concomitantly with loss of neurons (3). Although, amyloids are 
not restricted to neuronal environments. For example, they have been found to form in 
the pancreas in type 2 diabetics (4), and may even be systemic as in the case of AL 
amyloidosis (5). While amyloids have historically been viewed through the lens of 
pathogenicity, it has become increasingly apparent that organisms from all kingdoms 
of life exploit the amyloid structure for function.  For example, amyloids have been 
found to be components of human melanosome ultra-structures (6) and bacterial 
biofilms (7).  
Despite being detected as far back as 1854 by Rudolf Virchow and proven to 
be protein deposits in 1859 (8-10), it was not until 1959 and onwards that amyloids 
were structurally characterized, and experimental detection methods were developed 
(10, 11). Despite these advances and tremendous efforts into understanding the 
mechanisms of amyloid formation in the recent decades, no cure exists (12). Part of 
the reason why it has been so difficult to treat these protein deposits is the sheer 
complexity of the amyloid formation mechanism, where amyloid fibril formation may be 
induced from a myriad of factors, that are not necessarily mutually exclusive, such as 
oxidative stress (13, 14), chemical insult (15) and alterations to various homeostases, 
e.g. dysregulation of ion homeostasis (16) or proteostasis (17). In addition, the pathway 
to forming amyloid fibrils generally involves complex equilibria between monomers and 
different oligomer and fibril species (17). However, the complexity of amyloid fibril 
formation and propagation is not only limited to molecular mechanisms and local 
cellular environments. Recent understanding of Parkinson’s disease (PD) has revealed 
a significant involvement of the enteric nervous system in the development of the 
disease, as researchers have found that disconnecting the vagus nerve connecting the 
gastro-intestinal system to the brain results in a major reduction of PD incidences (18-
20). Additionally, amyloid fibrils of the protein central to PD, α-synuclein (αS), have 
been found in the gut and along the vagus nerve (21-23). Several factors may thus 
influence the initiation of PD, including gut microbiota and compounds ingested 
through diet (20). 
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The aim of the work in my thesis has been to provide a deeper understanding into 
amyloid formation mechanisms, and to study the interaction of an exogenous (fish β-
parvalbumin) and endogenous (Atox1) protein with the protein central to PD, αS. The 
observations presented in the thesis are based on work described in four research 
papers (denoted paper I-IV). Paper I shows that folded β-parvalbumin (β-PV) 
monomers form disulfide-bridged dimers, when the Ca2+ is absent, in an enzyme-
independent manner, resulting in highly amyloidogenic species capable of forming 
nuclei that may recruit monomers. Traditionally, investigations into the kinetics of 
amyloid fibril formation have been conducted in pure, dilute, solutions. While necessary 
to build the foundation of our understanding, several factors present in cells are absent, 
such as the excluded volume effect by macromolecular crowding, and protein 
interactions that may modulate this behavior. In order to simulate more cell-like 
environments, macromolecular crowding agents were employed, and it was observed 
that the excluded volume effect drastically promotes amyloid fibril formation of the 
folded protein, β-PV (paper II). Furthermore, investigating the interaction of fish β-PV 
with αS showed that β-PV in an amyloid form is capable of inhibiting αS amyloid fibril 
formation in vitro (paper III). Lastly, studying the interaction between the copper 
chaperone, Atox1, and αS, showed that copper loaded Atox1 is capable of interacting 








2 Protein folding, misfolding and 
amyloid formation 
The body is composed of trillions of heterogenous cells working together to achieve a 
functioning human (24). In order to build such a complex machine, four 
macromolecules are integral to the function. These are polysaccharides, lipids, nucleic 
acids and proteins. Lipids, unlike the other examples, are non-polymeric 
macromolecules, which are responsible for energy storage, signaling and structural 
components. Polysaccharides, in the form of glycogen, are a rapidly mobilizable 
energy reserve. Nucleic acids, which include DNA and RNA, are primarily responsible 
for coding and translating the blueprint for the linear protein building block sequence. 
Lastly, proteins are molecular machines that are capable of a wide array of activities 
based on their sequence. Among their many functions, they may act as structural 
support, signal relaying, catalysts, cellular gates and molecular motors; interacting in 
a massively intricate proteomic network. However, since proteins are responsible for 
most of the active functions within the body, they also become the primary culprit of 
non-infectious diseases when they malfunction. Modification to a building block, or 
altered sequence, may have effects that are usually either neutral or detrimental (25). 
Examples include relay proteins becoming permanently activated, as may occur in 
proto-oncogenes driving cancer (26), or structurally destabilized proteins, which may 
induce amyloidogenic diseases (27). 
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2.1 Protein folding 
Protein function is encoded in the sequence of its building blocks, known as amino 
acids, of which humans are known to utilize 21. Amino acids are organic compounds 
that have a carboxylic acid and an amine group, whose bonding links amino acids 
together, and they are differentiated by a side chains with varying functional groups 
(Figure 1). Humans only use α-amino acids, which means that the three groups are 
connected to the central carbon, and amino acids can be grouped based on polarity 
and charge at physiological pH. It is thus the sequence of functional groups along the 
peptide backbone that encodes the protein fold, structure, and activity, as the peptide 
chain has an optimal conformation where a stable local free energy minimum is met, 
based on carefully tuned entropic and enthalpic contributions (28).  
 
 
1  Amino acids (https://commons.wikimedia.org/wiki/File:Amino_Acids.svg) by Don Cojocari 
(https://commons.wikimedia.org/wiki/User:Dancojocari), licensed by CC-BY-SA 3.0 (https://creativecommons.org/licenses/by-
sa/3.0/legalcode). 
 
Figure 1 Illustration of the 21 eukaryotic proteinogenic α-amino-acids and their single and three letter code, 
grouped by charge, polarity and pKa values at physiological pH (7.4).1 
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Protein structures are described at four different levels; primary, secondary, tertiary 
and quaternary. Primary structure denotes the sequence of amino acids, secondary 
structure describes the local sub-structure of the protein, which forms primarily due to 
hydrogen bonds between the amide groups, whereas the tertiary structure refers to the 
three-dimensional structure of the whole peptide chain. Lastly, quaternary structure 
describes a multimeric complex between two or more individual peptide chains. As 
mentioned, it is the primary structure that imposes the final structure onto the protein, 
which is due to several interactions and constraints (28). A major constraint to possible 
protein conformations comes from the co-planar nature of the amide bond connecting 
the amino acids. Hence, bond rotation may only occur at the bonds around the α-
carbon (29). Beside the steric constraints, enthalpic interaction occurs within the 
protein chain in several ways. The backbone amide groups may form hydrogen bonds, 
i.e. between carboxyl oxygens and amino hydrogens, which give rise to local 
structures, most commonly α-helices and β-sheets. The structure of α-helices is a twist 
of the peptide chain into a helix, with 3.6 residues per turn, whereas β-sheets result 
from an interaction between two adjacent chain segments forming a flat sheet (30). 
Lastly, the side chains and backbone amide groups contribute to the tertiary and 
quaternary structure through different interactions. Proteins can be stabilized by ionic 
bonds (e.g. between glutamate and lysine), hydrogen bonds (e.g. between serine, 
glutamine and backbone amide groups), van der Waals interactions, and even 
covalent bonds in the form of cysteine disulfide bridges. However, protein structure is 
not only dependent on interactions within its own or other peptide chains, but also 
through interactions with the aqueous environment. Major examples include hydrogen 
bonding and ion-dipole interactions with H2O, as well as exclusion of hydrophobic 
residues from the aqueous environment, contributing to hydrophobic core packing. The 
latter is often known as the “hydrophobic effect”, as it increases the entropy of the 
water, which together with hydrogen bonds contribute the most to protein folding (31). 
The major force that counteracts these contributions towards the native state is the 
conformational entropy, as the peptide chain becomes restricted to fewer states.  
Despite the fact that the peptide chain may, in theory, have an unfathomable 
amount of conformations that it requires to sample in order to finally acquire the native 
state, while avoiding local energy minimum traps, proteins are capable of folding in 
very short time scales, from microseconds to seconds (32-34). To elucidate this 
apparent paradox, dubbed “Levinthal’s paradox” (35), Monte Carlo simulations were 
employed wherein folding of randomized amino acid sequences was investigated. It 
was found that only a fraction of these randomized sequences was fast-folding, and 
the sequences that were folding fast exhibited distinct energy minima (36, 37). Thus, 
the current hypothesis speculates that proteins initiate folding by obtaining a few key 
interactions, yielding a “native-like structural nucleus”, and subsequent native-like 
intermediates (38). This is typically considered the process for proteins that go through 
one or more stable intermediate states, that are separated from the unfolded and native 
state by one or more rate-determining kinetic barriers. Thus, as the protein gains more 
native-like interactions, the search for correct folding becomes more constrained, 
guiding the protein towards the native state (38). However, it might occur for the two-
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state folding proteins as well, where the unfolded protein passes an energy barrier to 
the native state in a seemingly single step, and thus only exists at an equilibrium of 
unfolded and folded states (38). In addition, it has also been observed that parallel 
pathways may exist depending on the protein, where multiple different intermediates 
converge to the native state (38, 39). A common representation of this folding process 
is the funnel-shaped energy landscape diagram, initially depicted by Wolynes, Onuchic 
and Thirumalai, which illustrates an energetically favorable process of folding that 
constricts the available conformational states as it progresses. The aforementioned 
intermediate rate-determining kinetic barriers are depicted as ruggedness and traps, 
and deep wells for the major intermediary species (Figure 2) (38, 40). However, not all 
proteins have an ordered three-dimensional structure, as is the case of intrinsically 
disordered proteins (IDPs). This flexible conformation allows IDPs to interact with many 
different partners by adopting compatible conformational states, which also include 
secondary structure elements such as α-helices (41). While the protein structure is 
encoded by the primary sequence and may readily adopt the fold in vitro, especially 
for small single-domain proteins, the conditions in vivo pose other issues. Such issues 
include folding during synthesis, with steric constraints within the ribosome, high 
concentration of nascent chains and initial long-range contact cannot be made as the 
protein is polymerized. To solve these issues, the cells employ protein chaperones 
(42). Chaperones bind folding intermediates in order to prevent aggregation, which 
may occur when e.g. hydrophobic patches are exposed and may be excluded from the 
aqueous environment through association with other proteins, resulting in e.g. 
amorphous aggregates (43). 
 
Figure 2  Simplified illustration of the energy landscape of protein folding. 
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2.2 Protein misfolding and amyloids 
As proper protein function within the proteome is crucial for survival, the cell employs 
a highly sophisticated set of tools that are capable of dynamically regulating a balanced 
and functional system. This “proteostasis” is ensured at several levels, from regulation 
of the peptide synthesis, utilization of chaperones to fold or rescue misfolded proteins, 
to the degradation network (44, 45). Nevertheless, despite such an extensive control 
system, proteins may still misfold, both spontaneously or by environmental induction, 
e.g. thermal, chemical or oxidative stress (45). Misfolded proteins, by themselves or in 
amorphous aggregates, can typically be rescued or degraded. Nevertheless, there are 
situations when the proteostasis network becomes overburdened, resulting in impaired 
clearance of misfolded protein species (45), which happens when e.g. oxidative stress 
becomes too great, as may occur with age (46). Formation of highly degradation 
resistant misfolded species such as aggregates in the form of fibrils is also a possible 
outcome, and of particular concern. Appearance of these species results in diseases 
known as “amyloidoses”, where the proteins form highly stable β-sheet rich fibrillary 
aggregates (Figure 3) (17). Diseases that are associated with the formation of amyloid 
fibrils vary greatly. They can be local, as in the case of islet amyloid polypeptide 
aggregating in the pancreas of type 2 diabetic patients, or systemic, as displayed by 
amyloid light-chain amyloidosis. They are, however, most often considered in the 
context of neurological disorders, e.g. Alzheimer’s disease and PD (17).  
Amyloid fibrils are a type of supramolecular polymers, consisting of proteins in 
β-sheet rich conformations, with the β-strands aligned perpendicularly to the fibril axis, 
known as the “cross-β fold” (17, 47). The amyloid fibrils are typically 7-13 nm in 
diameter and composed of 2-8 protofilaments, where each filament has an 
approximate diameter of 2-7 nm and they either associate laterally or twist around each 
other, although, mono-protofilaments have also been observed (17). At an atomic 
Figure 3 Simplified illustration of the protein energy landscape, with aggregates included. 
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level, studied by X-ray diffraction, two distinct reflections can be observed 
independently of the protein, at ~4.7 Å and 10-11 Å (48). These reflections correspond 
to the distance between the β-strands, and the distance between β-sheet layers, 
respectively. The β-sheet structure is stabilized by extensive hydrogen bonding 
between the amide groups of each chain, and this property is inherent in all proteins 
regardless of the side chains. In fact, this generic property is likely one reason that 
several pathological amyloid fibrils have been shown to be capable of “cross-seeding”, 
a process where an amyloid fibril of one protein can act as a template for monomers 
of another protein, thereby creating heterogeneous amyloid fibrils (49, 50). 
Furthermore, most proteins have high amyloid forming propensity sequences (51). The 
amino acid side chains are also involved in fibril stabilization, where they stabilize β-
sheet layer interactions by interdigitating side chains (“steric zipper”) as well as 
intermolecular stabilization  (52, 53). Together, these forces create an exceptionally 
stable protein species that, instead of occupying a local free energy minimum as the 
native fold does, are often considered to be the global minimum (Figure 3) (54). 
Interestingly, amyloid fibrils are often not homogenous species. A substantial degree 
of polymorphs has been identified from fibrils formed by a single protein, even in a 
single reaction mixture, in respect to protofilament count, arrangement and 
substructure (55). However, the field is currently shifting focus more towards the study 
of the pre-fibrillar oligomeric species. It has been discovered that these species appear 
to be the primary reason for cell toxicity, and some even speculate that the formation 
of fibrils is a last resort in order to reduce the oligomeric load, as inclusion bodies have 
been positively correlated with cell health (56-58). Albeit, oligomeric species are far 
more difficult to study than amyloid fibrils, due to their transient nature and significantly 




2.3 α-synuclein and Parkinson’s disease 
PD is a neurodegenerative disease that results in symptoms such as bradykinesia, 
rigidity and tremor, and is characterized by deterioration of dopaminergic neurons in 
substantia nigra (59). Concomitant with neuronal deterioration comes the appearance 
of Lewy bodies, that are considered the hallmark of PD, of which a major constituent 
is the protein αS in an amyloid conformation (60, 61). The vast majority of PD cases 
are idiopathic in nature, although there are rare familial forms (20). Furthermore, while 
PD is commonly thought of in the perspective of the central nervous system, 
accumulating evidence implicates the gut-brain axis to play a major role, where 
misfolded αS has been implicated to spread along the vagus nerve (18-20). In order 
for clinical symptoms to manifest, it is estimated that approximately 30 % of neurons 
are lost in substantia nigra (62), the trigger of which is thought to have occurred 
decades prior in the case of idiopathic PD (20, 63). While these triggers are largely 
unknown, there are indications as to of what nature they may be, through inference 
from the functions of PD risk genes and experimental animal work (20). Triggers that 
have been implicated include altered gut microbiota (64, 65), pathogens (66-68), air 
pollution (69), pesticides (70), heavy metals (71) and head trauma (72). These triggers 
may result in long-term gut dysfunction through impaired intestinal barrier (73), chronic 
inflammation (74) or pathogenic misfolding events as a result of direct interaction with 
αS (75). However, while misfolding of αS is typically considered a pathogenic event, it 
was recently speculated that it may also be part of a normal physiological response to 
infections (20, 67). Reasoning behind this includes healthy people displaying αS 
aggregates in the gut (21, 22), as well as an observed upregulation of αS in response 
to gastrointestinal infection of norovirus, including neutrophil and monocyte response 
to both monomeric and oligomeric αS (67). It was instead proposed that PD requires 
temporary or permanent facilitating events, concomitant with or following the triggers 
(20). These facilitators would allow triggers access, or aid in the pathological spread, 
into the central nervous system. For example, pesticides could trigger mitochondrial 
dysfunction, resulting in chronic production of reactive oxygen species, which in turn 
facilitate misfolding of αS (76, 77). Another example is irritable bowel syndrome, which 
is correlated with increased PD incidences (78-81), where inflammation results in 
impaired intestinal barrier function (82, 83), potentially facilitating the entry or spread 
of misfolded α-synuclein or other triggers to the nervous system (21, 22), as well as 
inducing oxidative stress (84). 
α-synuclein 
It was not until 1997 that αS was identified as a central protein in PD pathogenesis, as 
a mutation in the gene was observed in families with susceptibility to the disease (85). 
Significant efforts into understanding αS, its function and its involvement in the disease 
subsequently ensued, but the functions of the protein remain unclear (86). The function 
is primarily studied in a neuronal context, where it has been observed that there is an 
abundant expression of αS in various brain regions, e.g. substantia nigra, cerebellum, 
hippocampus, thalamus and neocortex (87, 88). Within the central nervous system, αS 
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is primarily concentrated at the presynaptic terminals (89), where it has been shown to 
associate with synaptic vesicles and is thought to be involved in neurotransmission 
and synaptic plasticity (90, 91). Several observations have been made in regards to 
the effect of αS on synaptic vesicles, including the regulation of synaptic vesicle pools, 
facilitating vesicular cell membrane docking, recycling and clustering, as well as acting 
as a chaperone by aiding the SNARE complex assembly (91-97). However, despite all 
the observations that have been procured over the last decades, there are still 
disagreements as to whether αS facilitates or prevents neurotransmitter release (98). 
Additionally, these observations appear to only scratch the surface of the true and 
complex nature of αS. Several observations indicate that αS is a pleiotropic protein, as 
it has been observed to e.g. regulate gene expression, apoptosis, neuronal 
differentiation, immune system response and modulating glucose and calmodulin 
levels (20, 99, 100). Expression of αS throughout a wide array of tissues has also been 
reported, as it has been observed in the peripheral nervous system, circulating blood 
cells, hematopoietic cells of the bone marrow, kidney, lungs, liver, heart, 
enteroendocrine cells and muscles (98, 101-103). 
αS is an IDP whose sequence can be divided into three domains, comprising 
the amphipathic N-terminal, non-amyloid-β component (NAC) and the acidic C-
terminal, together making up the 140 amino acid short protein (100). The amphipathic 
N-terminal allows α-synuclein to form an alpha-helix when binding to lipid vesicles with 
acidic head groups (Figure 4) (104, 105), with the first 25 residues binding tightly to the 
membrane, whereas the residues 26-97 have a weaker affinity but are inferred to 
regulate the affinity (106). The NAC region, comprising residues 61-95, is essential for 
the amyloid fibril formation of αS (107, 108). Interestingly, the highly homologous β-
synuclein protein does not form amyloid fibrils, and it has been implied that the reason 
for that is the absence of sequence homology in the NAC domain (109). The acidic C-
terminal, on the other hand, does not typically interact with vesicles. However, in the 
presence of Ca2+, whose influx at the presynapse occurs with electrical depolarization, 
the polarity of the C-terminal is reduced and it appeared to anchor vesicles to each 
other, and/or the plasma membrane (110). In addition, αS has also been shown to 
have a copper binding affinity, with binding constants (Ka, M-1) of 105-106 for Cu+, and 
107 for Cu2+ (111-114). Several residues have been identified as the binding site of 
Cu2+, primarily located in the N-terminal (residue 1-9), where Met1-Asp2 amide bond 
together with the Asp2 carboxylate and either H2O or His50, is a strongly proposed 
Figure 4 NMR solution structure of micelle bound αS (PDB: 1XQ8), with the N-terminal (blue), NAC region (red) 
and C-terminal (green) color coded. 
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complex (114). Cu+, on the other hand, has been shown to exhibit a preference for the 
sulfur atoms of Met1 and Met5, together with the Asp2 carboxyl group and H2O, 
creating a tetrahedral complex (114). While several studies have been performed on 
αS, less is known about the more physiologically relevant N-terminal acetylated 
variant, NAcαS (114-116). It was found that whereas Cu+ coordination remained 
unaffected by the acetylation (117), N-terminal coordination of Cu2+ was lost, and the 
ion was instead coordinated by the lower affinity His50 and Asp121 (118, 119). For this 
variant, the binding constant was reduced to 104-105 for Cu+ and 104 for Cu2+ (the 
latter, provided in (118) but taken from the value of His50 given in (111)) (118, 120). 
Additionally, the C-terminal appears to bind both Cu+ and Cu2+ around the same region 
as Ca2+, i.e around residue 120 (110, 117, 118). However, there is no free copper in 
the cytosol, which is instead regulated by high affinity copper binding proteins (121). 
Nevertheless, there are some indications that it may have copper dependent 
interactions in vivo. From cell work it could be seen that removing copper results in an 
increased cell membrane localization, whereas cells expressing C-terminally truncated 
αS were unaffected by copper levels (122). Copper bound αS has also been implicated 
in acting as a ferrireductase (123). Furthermore, free copper stored in neuronal 
vesicles is released into the synaptic cleft during electrical depolarization, resulting in 




2.4 Fish β-parvalbumin and dietary amyloids 
Since close to all proteins share the feature of containing amyloid competent 
sequences (51), it is not surprising that food proteins can form amyloids as well (126). 
In fact, amyloid fibril formation of dietary proteins has been explored to provide 
favorable qualities to food, e.g. transparent gelation properties (127), biodegradable 
and anti-oxidant colloidal stabilizer of iron-particles to treat iron-deficiency anemia 
(128), foam stabilizing antioxidant properties (129), and even food grade antibacterial 
hydrogels (130). Although, concerns of food protein amyloid fibrils are being raised due 
to the generic nature of amyloid fibrils, connection to pathogenicity and evidence of 
pathogenic spread from the gut of some proteins. Modified κ-casein amyloid fibrils 
displayed toxicity to PC12 cells in vitro, and feeding mice with amyloid fibrils of the 
disease-related apolipoprotein  A-II, or in vivo extracted serum albumin A, resulted in 
significantly accelerated misfolding throughout different organs of a mouse disease 
model, or deposition in organs of healthy mice, respectively (126, 131-133). 
Additionally, the major fish allergen, β-parvalbumin (β-PV), has been shown to form 
amyloid fibrils. These amyloid fibrils have been suggested to be the main 
conformational culprit of fish allergies, as human antibodies from fish allergic people 
bind a thousand-fold more strongly to the amyloid fibril conformation than to the 
monomeric one (134). Currently, apart from the modified κ-casein and β-PV, food 
protein amyloids have not been shown to have any adverse effects. In fact, some of 
the treatments to produce the amyloid fibrils are already in use in the food industry 
today, albeit not for purposes of amyloid fibril formation but rather food processing 
(126). While many food proteins have been identified to form amyloid fibrils, they 
typically do not do so under physiological conditions. Instead, low pH, low ionic strength 
and harsh heating (~80-90 ˚C) together with stirring are usually employed (126). Low 
pH results in two effects: hydrolysis of peptide bonds (135), and modulation of the 
amino acid charge distribution that significantly destabilizes the protein due to e.g. loss 
of salt bridges, protonation of aspartate and glutamate, resulting in loss of repulsion, 
or protonation of histidines causing repulsion of lysines and arginines (136-138). For 
β-lactoglobulin and ovalbumin it was found that at low ionic strength and pH, the 
resulting fibrils become long and semi-flexible, whereas higher ionic strength results in 
faster assembly but shorter and curly fibrils, which has been observed for β2-
microglobulin as well (139-142). Faster assembly with higher ionic strength appears to 
be a typical characteristic of fibril polymerization, and appears to be due to the 
electrostatic repulsion reducing the rate of assembly (140, 141, 143). However, in the 
case of ovalbumin it was found that the short flexible fibrils formed at higher ionic 
strength lacked a well-defined specific secondary structure, unlike the β-sheet rich 
fibrils formed at low ionic strength (143). Although, this effect of ionic strength on the 
fibril morphology and substructure may be less general. Amyloid-β peptide was found 
to form mature fibrils with higher ionic strength compared to low ionic strength that 
produced off-pathway immature fibrils, whereas αS and islet amyloid polypeptide 
displayed small or no differences at either low or higher ionic strength conditions, and 
some food protein amyloid fibril formation protocols make use of high ionic strength 
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(126, 144-147). Lastly, the high temperature disrupts the internal bonds and facilitates 
hydration of the buried residues (148, 149), resulting in denaturation of the protein, as 
well as facilitating pH induced hydrolysis of peptide bonds (150), thus exposing 
aggregation prone sequences. While the majority of dietary proteins require such harsh 
treatments, a food protein that readily forms amyloid fibrils under mild conditions is fish 
β-PV (151).  
Parvalbumin 
Parvalbumins are small ~12 kDa Ca2+ binding proteins (152). They belong to the EF-
hand family, which also includes calbindins, calretinin and calmodulin, among others 
(152). The term EF-hand stems from early X-ray structure investigations, of which 
parvalbumin isolated from carp muscles was the first one. It was found that 
parvalbumin contains three helix-loop-helix motifs: AB, CD and EF (Figure 5). The 
conformation of a single EF-hand domain is reminiscent of a hand with an extended 
thumb and index finger, with a curled middle finger (153, 154). The EF-hand domain 
has a 12 residue conserved motif (Table 1), which when searched for in the human 
genome reveals 242 proteins (155). Of all the EF-hand proteins, most have domains 
organized in pairs, an exception of which includes the parvalbumin family, that contains 
three domains (152). Two parvalbumin paralogues exist in mammals, α-parvalbumin 
(α-PV) and β-PV (152, 156). While both PV paralogues contain three Ca2+ binding 
 
Figure 5 NMR solution structure of Ca2+ bound Atlantic cod (G. morhua PDB: 2MBX) with the respective EF-
hand domains denoted. Ca2+ is displayed as green spheres, and the cysteine shown as a stick representation. 
Table 1 Conserved EF-hand domain motif. X, Y, Z and -Z are side-chain oxygen ligands, -Y denotes the 
backbone carbonyl ligand, whereas -X corresponds to a water ligand hydrogen-bonded to a loop residue. 
The most conserved residues and positions are bolded. 
1 2 3 4 5 6 7 8 9 10 11 12 
X  Y  Z  -Y I -X   -Z 
Asp  Asp  Asp Gly  Thr Asp   Glu 
  Asn  Asn Pro  Leu Ser    
  Glu  Ser   Val Glu    
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loops, the AB domain is inactive. However, it nonetheless fulfills a purpose of structural 
integrity, as well as to increase the Ca2+ binding affinity of PV, as shown by studies on 
the rat orthologues (157, 158). The AB domain does so by exposing its own 
hydrophobic sides toward the hydrophobic sides of the remaining EF-hands, thus 
acting reminiscent to that of Ca-calmodulin-peptide complex, but with an intramolecular 
C-terminal bound peptide instead (157, 158). In fact, remodeling the AB domain into a 
canonical EF-hand loop does not restore Ca2+ binding and destabilizes the overall 
structure, particularly in its apo-form, and it also increased the cooperativity of the two 
active Ca2+ binding domains (157). Furthermore, PV is not only capable of binding 
Ca2+, but also Mg2+ (152). Based on work with rat orthologues, it was shown that the 
CD- and EF-domains are capable of binding both ions in α-PV, whereas the CD-
domain of β-PV acts as a Ca2+ specific loop (159, 160). In addition, while rat α-PV is 
relatively unaffected in its conformational state as it transitions between apo- and Ca2+ 
bound forms (161), rat β-PV undergoes significant structural reorganization of the 
hydrophobic core when Ca2+ is removed from the Ca2+ specific CD-domain (160). It 
should, however, be noted that the literature has often treated lower vertebrate β-PV 
(e.g. fish and frog) as direct orthologues to mammalian β-PV (also known as 
oncomodulin), due to many shared essential features. However, with more refined 
phylogenic analysis, it has recently been shown that while mammalian α-PV has a 
closely shared phylogeny with lower vertebrates, β-PV does not (162). Indeed, some 
evidence can be observed in the literature, where it has been reported that lower 
vertebrate β-PV does in fact bind Mg2+ at two sites (163). Additionally, tissue 
expression of β-PV differs greatly between lower vertebrates and mammals, where it 
has been shown that lower vertebrates express β-PV in muscles (152, 164), whereas 
mammals only express α-PV (165, 166). Expression of β-PV in mammals has instead 
been shown to be limited to the outer hair cells, vestibular hair cells, placenta, and 
secreted by macrophages (167-170). It was initially assumed that PV only acts as 
intracellular Ca2+/ Mg2+ buffers (159), due to the slow exchange rate (171) and two high 
affinity Ca2+/Mg2+ mixed sites (163, 172), where it would return Ca2+ from the myofibrils 
to the sarcoplasmic reticulum (173-175). However, single Ca2+ binding properties, as 
displayed by mammalian β-PV, are usually characteristic of Ca2+ binding proteins that 
have signal transduction characteristics, as they allow fast and dramatic 
conformational changes. Therefore mammalian β-PV was also speculated to be a 
signal transduction protein (159). Additionally, and not mutually exclusive to the latter 
hypothesis, it was also suggested that the conformational change induced by Ca2+ 
binding to the CD domain is designed so to impart an energetic penalty upon Ca2+ 
binding, resulting in a modulation of Ca2+ binding affinity (160, 176). In terms of amyloid 
fibril formation, fish β-PV has specifically been shown to readily form amyloid fibrils 
under physiological conditions (151). It was shown that under simulated gastric fluid, 
i.e. pH 2, or addition of EDTA at pH 7.4, fish β-PV readily formed amyloid fibrils that 
conferred a protection against proteolytic attacks (151). It was thus speculated that the 
low pH of the gut protonates the coordinating ligands of β-PV, resulting in a release of 
Ca2+, and thus destabilizing the protein (151), and it was further shown that chelating 
Ca2+ from β-PV results in an expanded conformational state (177). Additionally, 
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antibody reactive epitopes could be observed in the blood following a meal of fish, 
insinuating that it may traverse the intestinal barrier (178). Mechanistically, it was 
identified that the highly conserved cysteine of β-PV may play a key role in the amyloid 
fibril formation, as a C19S mutant resulted in an increased lag time before forming non-
fibrillar Thioflavin T reactive aggregates, with an incomplete β-sheet transition and 




2.5 Amyloid fibril formation mechanisms 
During amyloid fibril formation proteins go through a thermodynamically unfavorable 
process, leading to the formation of nuclei. Nuclei may be regarded as the smallest 
species capable of initiating fibril elongation, but can also be regarded as the smallest 
aggregates where addition of monomers occurs at a faster rate than dissociation (17, 
179), the latter definition of which will be used henceforth. The process leading to nuclei 
differs depending on whether the native protein is an IDP or folded (Figure 6A). For 
IDPs, disordered or partially disordered monomers may convert directly into elongation 
competent nuclei, or they may go into highly disordered or partially structured transient 
oligomers, followed by internal reorganization into a more stable β-sheet containing 
structure (Figure 6C). These oligomers are then capable of further growth by monomer 
addition or oligomeric self-association, eventually forming fibrils (17, 180). The process 
is, as stated, slightly different for natively folded proteins. While it is hypothesized by 
some that close to all proteins can form amyloid fibrils under the right conditions (54), 
the amyloid competent sequences have been estimated to be exposed at the surface 
of folded proteins in only 5.3 % of the cases, and less than 0.1 % of these comprise 
geometrical compatibility with self-complementary β-sheets (51). In line with this, it has 
been observed that folded proteins initiate amyloid fibril formation by exposing 
aggregation prone sequences as a result of thermal fluctuations, ligand release, or 
local unfolding, thus circumventing the major energy barrier of unfolding (181). These 
partially folded intermediates may then form nuclei directly, go into partially structured 
oligomers followed by, as for IDPs, structural conversion to β-sheet rich oligomers, or 
associate into native-like aggregates that are capable of converting into amyloid-like 
oligomers and fibrils (17). However, further complicating matters is the typically 
heterogenous population of different types of oligomers. They may be on- or off-
pathway towards amyloid fibril formation, and they are meta-stable and transient in 
nature, thus difficult to study (17). In addition to the formation of the primary nucleus, 
secondary processes that increase the aggregation rate through formation of growth 
competent species may also take place for both IDPs and folded proteins, depending 
on the protein and physicochemical conditions. For example, fragmentation of the 
fibrils increases the number of growth competent species, and secondary nucleation 
wherein the surface of the fibrils catalyzes the formation of new oligomers and nuclei 
can occur (17, 182) (Figure 6B).  
Amyloid fibril formation typically follows sigmoidal kinetics, with an initial lag 
phase, followed by an exponential phase and lastly an equilibrium phase (Figure 6B) 
(17, 182). During the lag phase the aforementioned processes described above occur 
in a highly dynamic fashion, where metastable oligomers associate and dissociate in 
multiple competing pathways (180), with a rate-limiting step being either the direct 
conversion to a nucleus, or the structural reorganization into a β-sheet containing 
oligomer (180). This does not mean that nuclei do not exist during the lag time. In fact, 
for amyloid-β peptide, with a lag time of 33 minutes, it was estimated that the first 
nucleus appears after 3 μs (179). Thus, fibrils form already in the lag phase, where the 
length of the phase also depends on the elongation rate, and secondary processes if 
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they exist in the system. Furthermore, monomers or fibrils will always be the dominant 
species in the solutions, with only few oligomers at any given time point (179). As 
enough nuclei have formed, or fibrils in systems with secondary processes (where the 
fibril surface catalyzes formation of new nuclei, or fragmentation events form new 
ends), the kinetics transitions to the exponential phase, where fibril mass formation 
increases to its maximum rate. Following this phase comes the equilibrium phase. 
Since all the processes occur continually independent of the phase, the fibril mass is 
at an equilibrium in respect to protein association, nuclei formation and dissociation 
(17, 179).  
 
Figure 6 Proposed amyloid fibril formation mechanisms. (A) Nucleus formation of IDPs and folded proteins, with 
vertical boxes representing different stages of the amyloid fibril formation process. (B) Typical sigmoidal amyloid 
fibril formation kinetics (represented by amyloid-β in this graph) (left), and the different key microscopic steps 
involved in amyloid fibril formation (right). (C) Illustration of the structural reorganization during oligomer 
formation. Adapted with permission from ref (17). 
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2.5.1 Modulation of amyloid fibril formation by protein and ligand 
interactions 
Amyloid fibril formation can be modulated at all the stages, from the monomeric to the 
fibrillary stage. Monomeric proteins can either be stabilized from progression towards 
oligomers or guided towards either off- or on-pathway oligomers. Oligomers 
themselves can be disassembled into monomers, structurally reorganized into non-
toxic off-pathway species, or can be prevented from forming nuclei. Lastly, fibrils can 
seed and cross-seed amyloidogenic proteins by templating them into the amyloid 
conformation, resulting in fibril elongation, or guide them towards nuclei by means of 
surface catalysis. Surprisingly, amyloid fibrils of different protein species have even 
been shown to prevent amyloidogenic proteins from aggregating. A few examples will 
be described henceforth, of both endogenous and exogenous sources. 
Naturally occurring endogenous modulators of amyloid fibril formation are, as 
has been touched upon, chaperones. Chaperones consist of many different proteins, 
often working together, and they may stabilize the native fold of amyloidogenic proteins 
during de novo folding or prevent the aggregation when the native state is destabilized 
(183). As such, chaperones have been shown to interact with several species in the 
amyloid fibril formation chain. They may inhibit formation of both oligomers and amyloid 
fibrils by stabilizing the monomeric state or, interestingly, direct the protein into 
amorphous aggregates (58, 184). Chaperones have also been found to be capable of 
binding oligomers, thus interfering with primary nucleation, as well as binding to the 
ends and surfaces of fibrils, resulting in reduced elongation and secondary nucleation 
rates (185, 186). Notably, while amyloid fibrils have long been considered dead end 
species that the cell is unable to clear, recent findings suggest that this may not be the 
case. The chaperone heat shock protein (Hsp) 104, found in Saccharomyces 
cerevisiae in 1990, is known as a “disaggregase”. It is capable of solubilizing large 
protein aggregates, including amyloid fibrils (187, 188), and together with Hsp40 and 
Hsp70, may even rescue enzymes (189). While Hsp104 is highly conserved in 
eubacteria and eukaryotes, it has no homolog nor ortholog in metazoa (190). However, 
in 2011 it was found that Hsp110, together with Hsp40 and Hsp70 was capable of 
disaggregating and reactivating proteins in amorphous aggregates, but with little effect 
on amyloids (188). Following this it was found that heat shock cognate 71 kDa protein, 
Hsp40 and Hsp110 were capable of rapidly disassembling αS fibrils in vitro (191). This 
highlights how the cells have a wide array of chaperones that achieve different tasks 
depending on the circumstance, and work together in a fascinatingly modular fashion. 
While homologous seeding is straightforward, heterologous seeding is less so. 
However, as the amyloid fibril is a supramolecular polymer that shares structural 
features and interactions independent of protein species (48), it is not surprising that 
some can cross-seed (49, 50). It may occur from endogenous sources, as it does for 
amyloid-β peptide, islet amyloid polypeptide, and tau monomers co-aggregating with 
α-synuclein (192-195), or acceleration of αS aggregation in the presence of the 
respective fibrils. It may occur by exogenous sources, as was shown with the functional 
bacterial amyloid CsgA monomers and fibrils accelerating αS aggregation (64). A 
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potential explanation of these differences may stem from structural similarity of the 
formed fibrils, rather than sequence similarity (49). Albeit, cross-seeding may not occur 
at all, or, interestingly, it may in some cases occur cross-inhibitory, or even 
unidirectionally (49). Examples of inhibitory reactions include pro-islet amyloid 
polypeptide that is, in both monomeric and fibrillar form, capable of preventing amyloid 
fibril formation of α-synuclein (192). Unidirectional cross-seeding, on the other hand, 
may be a result of the protein fibrils conformational plasticity, as observed by the 
myriad of polymorphs (55). Therefore, a protein (A) with a set of conformational 
polymorphs, where one or more conformations can adopt the structure of another 
amyloidogenic protein (B), then A may be seeded by B. However, if the conformational 
state of B is not preferred by A, and thus not propagated when A is aggregated in 
isolation, the converse might not occur, therefore leading to unidirectional cross-
seeding (196, 197). Intriguingly, secondary nucleation has been indicated to impart the 
structure of the parent fibril, as was shown when different amyloid-β peptide mutants 
were cross-seeded. Different mutants formed different morphologies, and only the 
mutants with the same polymorphs were capable of cross-seeding, independent of 
hydrophobic patches (198). It should, however, be noted that the fibril substructure was 
not resolved. 
As described, the amyloid competent sequence is generally buried in the core 
of folded proteins (51), and exposure of it may occur, or be prevented, due to ligand 
release or binding, respectively (17). This has been observed in several cases, e.g. 
transthyretin (TTR), superoxide dismutase 1, acylphosphatases and β-PV (151, 199-
202). In the case of TTR, a primary carrier of thyroxine, both hormone analogues and 
small aromatic molecules were found to stabilize the quaternary native state by binding 
the thyroxine binding sites (199). Acylphosphatases from Sulfolobus solfataricus and 
Drosophila melanogaster have been shown to form amyloid-like aggregates in the 
absence of initial unfolding. However, it was observed that a competitive enzyme 
inhibitor (inorganic phosphate) was capable of stabilizing the native state of the protein 
and prevent amyloid-like aggregate formation (202).  More general examples are 
polyphenols. They are well known to interact with amyloidogenic proteins, where (-)-
Epigallocatechin-gallate (EGCG) is especially well studied, and has been shown to 
prevent amyloid fibril formation of both natively folded proteins and IPDs (203). EGCG 
is capable of binding both monomeric and oligomeric species, directing the monomers 
towards off-pathway β-sheet poor aggregates, and even remodels pre-formed toxic 
oligomers (204, 205). It appears to do so in a complex manner, where it forms 
hydrogen bonds with both the amide groups and side chains, in addition to hydrophobic 
interactions (206). However, EGCG has also been shown to covalently modify 
proteins, which may be a contributing factor to the inhibitory effect (207). Superoxide 
dismutase 1, involved in amyotrophic lateral sclerosis, is a homodimeric metalloprotein 
primarily known for disproportionation of superoxide into oxygen and hydrogen 
peroxide (200). It requires Cu2+ for enzymatic activity and Zn2+ for structural stability 
(208, 209), where demetalation of superoxide dismutase 1 has been shown to 
destabilize the protein, and mutations in the zinc-binding loop have been correlated 
with enhanced hydrophobicity and misfolding (200). In addition, small molecules have 
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been shown to bind to the dimer interface cavity, at a position where introduced 
disulfide bonds resulted in dimer stabilization and misfolding prevention (201). 
However, it should be noted that in vivo amyloid fibril formation of superoxide 
dismutase 1 is still contested, despite in vitro formed aggregates showing a negative 
circular dichroism peak at 220 nm and reactivity by the amyloid binding fluorescent 
dyes, congo red and Thioflavin T (210, 211).  
Several metal ions have been implicated in the progression of 
neurodegenerative amyloidoses, both due to long term environmental exposure and 
alterations in metal homeostasis (16). The effect of metal ions is a complicated 
relationship, where the effect may be on tissue and cellular level, e.g. increased 
oxidative stress, altered signaling and metabolic changes, or on a molecular level, e.g. 
direct interaction with amyloidogenic proteins (16). In the case of direct interaction, 
there are several ways metal ions may influence amyloid fibril formation. Metal ions 
may rearrange the peptide backbone, as was shown for Cu2+ induced cis-trans 
isomerization of proline in β2-microglobulin, resulting in distal oligomerization interfaces 
that promote amyloid fibril formation (212). Inter-molecular protein association may 
also be induced through metal ion coordination complexes, e.g. several amyloid-β 
peptide molecules coordinating Zn2+ by histidine, thereby promoting oligomerization 
and amorphous aggregation rather than amyloid fibril formation (213-215). Chemical 
modification of proteins by metal ions is also a possibility, as was shown for N-
terminally acetylated αS (NAcαS) bound to Fe2+ under aerobic conditions, resulting in 
Schiff base formation and reversible intermolecular covalent bonds that lock the protein 
in an oligomeric state. In contrast, Fe3+ and anaerobic conditions prevented this from 
occurring and instead resulted in amyloid fibrils, leading the authors to conclude that 
Fe2+ may reductively activate O2, that then may oxidize NAcαS or protein partners (216). 
While it did not occur in this study, such a reaction may also yield tyrosine 
hydroxylation, oxidation and/or dityrosine cross-linking (217), which is a feature of αS 
in Lewy bodies (218).  
2.5.2 Effect of macromolecular crowding on protein aggregation 
The intracellular environment is estimated to have 80-400 mg/ml macromolecules, 
which corresponds to a volume occupancy of 5-40 % (219, 220). Extracellular space 
also displays high concentrations of macromolecules, where e.g. blood has been 
shown to have a protein concentration of 60-80 mg/ml (221). This mixture of 
macromolecules results in many effects due to its heterogeneous nature, including 
non-specific chemical interactions (e.g. electrostatic and hydrophobic interactions) and 
an effect known as “excluded volume”. The latter is a major effect that arises from the 
inaccessibility of surrounding space. The excluded volume reduces the available space 
wherein the protein can conformationally rearrange, and thus the configurational 
entropy, resulting in more compact states. A similar effect can generally be observed 
by protein-protein interactions, whereby association reduces occupied space, thereby 
increasing the entropy of the system in both cases as a result of increased number of 
crowder configurations (219, 222). Excluded volume thus stabilizes natively folded 
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states (Figure 7), as well as interactions with other macromolecules, e.g. multimers. 
Yet, as the amyloid fibril state is a highly compact polymer, this would imply that the 
amyloid fibrils themselves should be favored, as well as the on-path association 
reactions into oligomeric states. It has been observed for many amyloidogenic IDPs, 
which occupy a larger volume compared to more structurally ordered proteins, that 
macromolecular crowding agents appear accelerate amyloid fibril formation (223-225). 
The effect is, however, less straightforward for natively folded proteins. While natively 
folded proteins exist in a local free energy minimum (226), and this energy minimum is 
further stabilized by macromolecular crowding agents (219), they do not necessarily 
need to cross the major energy barrier of unfolding to become amyloidogenic (17). 
Thus, rather than significant unfolding, association of these aggregation prone 
sequences during partially destabilizing events may initiate the misfolding, followed by 
entry into the misfolding funnel that is further exacerbated by macromolecular 
crowding. In accord, several folded proteins have shown increased stability against 
amyloid fibril formation under macromolecular conditions, e.g. bovine carbonic 
anhydrase (227), bovine core histones and insulin (225), with the latter two existing in 
multimeric states at physiological conditions. However, in destabilized native states, 
i.e. by low pH, an accelerated aggregation under macromolecular crowding conditions 
could be observed, which also held true for β2-microglobulin (225, 227, 228). It was 
also speculated that since the multimeric states of bovine core histones and insulin 
prevent aggregation, macromolecular crowding facilitates multimers, whereas low pH 
shifts the equilibrium towards aggregation prone monomers (225). Additionally, 
another folded protein, apolipoprotein C-II, aggregates in the absence of lipids, and 
this was further facilitated by crowding (229). It can thus be observed that 
macromolecular crowding tends to stabilize folded proteins in their native states. Albeit, 
during destabilizing events the proteins may start to expose aggregation prone 
sequences that associate, which can be further exacerbated by macromolecular 
crowding agents directing them down the “misfolding funnel”. 
 
Figure 7 Simplified illustration of folding energy landscape of a protein in presence of macromolecular crowding. 




However, macromolecular crowding does not necessarily alternate between 
stabilization of native protein states and facilitation of amyloid fibril formation. If several 
aggregation pathways exist, macromolecular crowding may trap the protein in an 
alternate thermodynamically stable, misfolded, conformation. (183). This was shown 
for αS in macromolecular crowding conditions together with various alcohols and 
trimethylamine-N-oxide, which, depending on concentrations, allows parallel 
aggregation species (225). In addition, when human islet amyloid polypeptide was 
incubated with macromolecular crowding agents, amyloid formation was attenuated. 
Instead, the authors noted an accumulation of off-pathway non-toxic oligomers, in 
place of the typically toxic end-products (230).  However, while these studies have 
been made in vitro, it should be noted that a functioning proteostasis network would 
likely work to prevent the misfolding funnel in vivo for both IDPs and folded proteins. 
2.5.3 Effect of osmolytes on amyloid fibril formation 
Stabilizing osmolytes also play a role in the cell, where it has been shown that they are 
upregulated or imported during conditions of stress, thus promoting the proteins native 
fold (231-234). Such osmolytes include small polyols, sugars, amino acids and methyl 
amines, that induce and stabilize the protein fold through enthalpic contributions, rather 
than entropic contributions as displayed by macromolecular crowding (219, 220, 233, 
235, 236). Through studies of 48 different proteins with several different osmolytes it 
has been found that interaction of stabilizing osmolytes with the protein backbone is 
unfavorable. Additionally, charged side chains have the most favorable interactions, 
whereas polar side chain contributions are smaller or negligible, and apolar side chains 
tend to be negligible or slightly unfavorable. Interestingly, while some osmolytes 
increase the solubility of proteins through favorable side chain interactions (e.g. glycine 
betaine and proline), others decrease solubility as the unfavorable interactions with the 
backbone outweigh the favorable side chain interactions, despite stabilizing the native 
state (e.g. trimethylamine N-oxide) (236). Thus, the strong aversion against the amide 
groups favors a compacted protein (known as the osmophobic effect), albeit with a 
preferential interaction with the charged side chains, which in turn favors the folding of 
proteins. Despite this, the mechanism of action of stabilizing osmolytes is not known, 
and several proposed models exist, although not mutually exclusive. For 
trimethylamine N-oxide alone, it has been proposed that it may stabilize compact 
conformations through direct interactions (237, 238), interact favorably with the 
heterogeneous surface of folded proteins as a surfactant (239), act as a crowding 
agent and thus contribute entropically (235, 240), or reduce the hydrogen bonding 
ability of water, thus favoring amide group hydrogen bonding, as occurs in the protein 
core (222, 234, 240, 241). As can be surmised, osmolytes will also modulate protein 
aggregation (242). For the folded amyloidogenic proteins, P39A cellular retinoic acid-
binding protein, insulin and immunoglobulin light chain, it was shown that various 
osmolytes stabilized the native state, thus preventing amyloid fibril formation (231, 232, 
243). However, for several IDPs it was shown that the osmolytes trimethylamine-N-
oxide, glycerol and glycine betaine enhanced the amyloid fibril formation (244-246). 
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Furthermore, and akin to macromolecular crowding, the effect of osmolytes on IDPs 
was shown to alternate between facilitation and inhibition of amyloid fibril formation 
(242). At high concentrations, the effect of trimethylamine-N-oxide on αS displayed an 
off-pathway aggregation into alpha-helical oligomeric states (245). Furthermore, an 
extensive investigation into human islet polypeptide aggregation showed that 
osmolytes stabilize proto-fibrillary structures, rather than amyloid fibrils, without 
affecting the morphology of the mature fibrils (247). However, human islet polypeptide 
was, in the presence of proline, redirected into amorphous aggregates instead of 












This chapter is intended to give a brief description of the techniques used within this 
thesis. This section does, however, not aim to give detailed experimental methodology, 
which can instead be found in the respective papers. 
3.1 Protein expression 
Protein expression can be performed by a variety of organisms, all of which have 
different advantages and disadvantages (249). The work performed in this thesis was 
done with proteins expressed by the work horse, E. coli, and this section will therefore 
focus on this expression system. A highly popular E. coli expression system involves 
the T7 promoter, where the gene is inserted into a plasmid containing the promoter 
sequence recognized by the phage T7 RNA polymerase (250). The phage T7 RNA 
polymerize gene itself is commonly placed in the genome of the expression system 
under control of the lacUV5 promoter. Unlike the prototypical lac promoter, the lacUV5 
displays reduced catabolite repression due to three point mutations, and protein 
expression may thus be induced by lactose, or the non-hydrolyzable analogue 
isopropyl β-D-thiogalactopyranoside, even in presence of glucose (249, 251). Addition 
of IPTG is then typically done mid log phase of E. coli, as the growth stage typically 
has the maximal protein translation, although early stationary phase can be used as 
well if e.g. formation of inclusion bodies is an issue (249). The plasmid containing the 
gene of interest typically includes a selection marker, where antibiotic resistance is 
commonly used (249). Thus, by growing E. coli in media containing the selected 
antibiotics, only bacteria with the resistance gene, i.e. plasmid, will survive. This 
26 
 
ensures that the plasmid is not lost, as plasmid-free bacteria are more metabolically 
competitive. After induction and protein expression the bacteria are typically lysed to 
extract the protein, followed by purification through various means, which often is fast 
protein liquid chromatography systems. 
3.2 Fast protein liquid chromatography 
For analytical scale protein preparations, the cell lysis homogenate is typically cleared 
by centrifugation, wherein the protein remains in the supernatant. After recovering the 
supernatant, several procedures can be used to purify the protein of interest, based on 
its properties. These include solvent, pH, ionic strength, charge, size and structural 
features. To purify based on these features, chromatography is typically employed. 
Chromatography is essentially a technique that is based on partitioning of a compound 
between two nonmiscible phases, consisting of a stationary phase and a mobile phase. 
For protein purification, the stationary phase is typically attached to an inert matrix, with 
a liquid mobile phase flowing through it, often with the aid of a pump system, 
hydrostatic pressure or gas pressure. The most common method is the fast protein 
liquid chromatography system, and a few of the available separation techniques will 
be covered in this section, based on the textbook by H.G Pontis (252). 
Affinity chromatography 
A powerful technique that employs a well-known and defined structural feature of the 
protein is the affinity chromatography, which may in a single step purify a target protein 
several thousand-fold from the crude lysate. In the technique, the stationary phase can 
include e.g. immobilized ligands, a cofactor, receptor or antibodies. A highly popular 
form of affinity chromatography is the immobilized ion affinity chromatography, wherein 
transition metals such as cobalt, nickel, copper and zinc are immobilized. This 
stationary phase can then selectively bind proteins with affinity towards the ions. Such 
a binding feature can be engineered onto recombinant proteins of interest, in the form 
of fusion proteins, where the his-tag is exceedingly common. The histidines readily 
form coordination complexes with nickel and cobalt, by binding with their imidazole 
groups. In order to elute the subsequently immobilized protein, increasing 
concentrations of free imidazole can be added, that will compete with the his-tag for 
binding of nickel or cobalt and thus release the protein. Another option is to decrease 
the pH, which will protonate the histidine and disturb the coordination with the ions. 
Lastly, the his-tag is typically connected by a short chain segment that is recognized 
by a specific protease, e.g. thrombin or tobacco etch virus protease. The his-tag can 
then be specifically removed upon addition of the protease and purified from the 
protein.  
Ion-exchange chromatography 
The charge of the target protein is another feature that is commonly exploited in the 
purification procedure. The principle is based on ionic interactions of the protein with 
the stationary phase, which depend on the isoelectric point and pH of the buffer, and 
may result in a 10-fold degree of purification. A pH below the isoelectric point results 
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in a positively charged protein, whereas above results in a negatively charged protein. 
Thus, depending on the pH, the protein will interact with different affinities towards the 
charged stationary phase.  This is, however, a simplified picture, as discrete charges 
on the proteins, in particular the surface, play a role as well (253). The most common 
strategy to elute the protein involves an increasing ionic strength of the mobile phase, 
where proteins will elute depending on the cumulative strength of the ionic interaction.  
Size-exclusion chromatography 
Size-exclusion chromatography is a very useful technique in two ways. First, it provides 
further separation of proteins based on their sizes, as well as a complete buffer 
exchange into the buffer of interest. Thus, it may e.g. remove the large amount of 
imidazole following immobilized ion affinity chromatography, or the potentially highly 
ionic buffer after ion-exchange chromatography, both of which may interfere with 
subsequent studies or applications. Size-exclusion chromatography employs a matrix 
of porous beads, where size-compatible proteins are slowed down within the column 
by entering the porous networks, whereas proteins too large to enter pass by the 
beads. This results in a size-dependent elution distribution of proteins, with larger 
proteins eluting first, followed by smaller and smaller proteins. Depending on the 
protein of interest, the beads are cross-linked to different degrees, with a higher degree 
of cross-linking to resolve smaller proteins from each other. 
3.3 SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE) is a common technique 
used to separate and analyze proteins. It works, in principle, by applying an electric 
field, resulting in migration of proteins through a cross-linked gel matrix. However, as 
proteins are molecules with varying charge and tertiary structures depending on 
species, they will not migrate uniformly throughout the gel. To achieve size-based 
separation, the anionic surfactant SDS is used, which denatures the proteins (often 
combined with heating) resulting in linearized proteins, thus avoiding the issue of the 
protein fold in gel migration. SDS also covers the protein with negative charges, 
resulting in an approximately equivalent charge-to-mass ratio independent of protein 
species, thus allowing separation of proteins based on mass. Reducing agents may 
also be used, that will cleave disulfide bonds. The protein in the gel can be analyzed 
after the electrophoresis by several techniques, including Coomassie staining, which 
binds and visualizes proteins, Western blot, in which antibodies are used for visualizing 
specifically the protein of interest, and mass-spectrometry. 
3.4 UV-vis spectroscopy 
Electromagnetic radiation can be described both as a wave, with the electric and 
magnetic field oscillating perpendicular to each other, and as an energy package with 
particle-like properties, known as a photon. The study of the interaction of matter with 
electromagnetic radiation as a function of wavelength or frequency is known as 
spectroscopy, which, in the case of ultraviolet-visible spectroscopy corresponds to 
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~200 nm – 800 nm. The textbooks about fluorescence (254) and circular dichroism 
(255) can be read for more in depth information. 
3.4.1 Absorption spectroscopy 
One mechanism in which UV-vis light interacts with matter includes absorption, 
wherein the matter absorbs the photon. In an atom or molecule, electrons only exist in 
quantized energy levels, determined by the electron configuration. Only when the 
energy of the photon matches the difference of these quantized energy levels (ΔE) 
may it be absorbed, resulting in a rearrangement of the electrons into an excited state. 
The absorption process can be described by Bohr’s frequency condition ((1), which 
takes Plank’s constant (h) and the frequency (v), speed (c) and wavelength of light (λ) 
into account. 
 (1) 
Thus, different atoms and molecules absorb different wavelengths of electromagnetic 
radiation, giving rise to absorption bands. Furthermore, the electronic wave function 
overlap between the two states determines whether the transition will occur or not, and 
the likelihood of transition. As a result, the intensity of absorption will vary with 
electromagnetic wavelength. This phenomenon can be applied by spectroscopy, by 
measuring the relative intensity of the light before (I0) and after (I) interaction with the 




This can be further used to measure the concentration of the chromophore, as 
chromophores will have a molar extinction coefficient (ε), which is a measure of how 
strongly the chromophore absorbs light at a given wavelength. By knowing the molar 
extinction coefficient, the optical path length (l), one can apply Lambert-Beer law to 
calculate the concentration (c) (3). For proteins, the chromophore is usually the amino 
acid residues tryptophan, tyrosine and cystine measured at 280 nm, whose cumulative 
extinction coefficient can be used to measure the protein concentration. In addition, 
phenylalanine can also be used to measure the concentration, as it has a maximal 
extinction coefficient at 257.5 nm. 
 
cl (3) 
Absorption spectrophotometers contain a light source, a monochromator (which only 
allows the selected wavelength to pass) and a beam splitter that diverts the 
electromagnetic radiation to both the reference detector and through the sample to the 
sample detector (Figure 8).  
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3.4.2 Fluorescence spectroscopy 
Upon absorption, the system may excite to either singlet (Sn) or triplet states, which 
are described relative to the ground state (S0). Triplet states will, however, not be 
considered in this thesis. There are also several vibrational states for each electronic 
state (Figure 9). 
As the singlet states are energetically unfavorable, they are typically short lived, 
and there are several ways the system relaxes. Vibrational relaxation to the lowest 
vibrational state of the excited state (Sn+1) occurs quickly, often followed by non-
radiative internal conversion (Sn+2 to Sn+1) and non-radiative relaxation (S1 to S0). While 
this represents the most common mode of system relaxation, there are also molecules 
known as fluorophores, whose relaxation is radiative. As the vibrational relaxation is 
the fastest regardless, emission of a photon as the system relaxes to S0 typically 
occurs from the ground state of the excited state, thus resulting in a lower energy 
emission compared to the absorbed photon (redshift). In addition, as the emission 
almost always occurs from the ground state, the energy of the emitted photon is 
independent of the absorbed photon (Figure 9).  
 
Figure 8 A schematic of an absorption spectrophotometer, where the incident light passes through a 
monochromator that only allows the specified wavelength through (I0), which is then split to the reference detector 
and through the sample (I) to the sample detector. 
 
  
Figure 9 Left: Schematic of a fluorometer, where only the selected wavelength passes through the 
monochromator and reaches the sample. The sample is then excited, and subsequently emits photons that are 
further selected through a second monochromator before reaching the detector. Right: Simplified Jablonski 
diagram displaying the different modes of system relaxation following excitation, where hva1 and hva2 
correspond to photons of different wavelengths exciting the system, and hvf1 and hvf2 to emitted photons. 
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A fluorometer is used to measure fluorescence and it is very similar to absorption 
spectrophotometers. The light passes through a monochromator and excites the 
sample, which then fluoresces omnidirectionally. This emitted light then passes 
through a second monochromator and into the detector, which is typically situated 90˚ 
from the initial light source, as to avoid measuring incident light (Figure 9). Both 
emission and excitation spectra can be measured with this instrument. To measure an 
emission spectrum, the incident light wavelength can be fixed, and the emitted light 
detected over a selected range. In converse, excitation spectra can be measured by 
fixing the excitation wavelength and exciting the fluorophore over a selected range. 
A major technique used in this thesis employs the fluorescent amyloid fibril 
binding dye, Thioflavin T (ThT), whose fluorescence quantum yield increases 
drastically upon binding amyloid fibrils. This dye was used to monitor the bulk amyloid 
fibril formation kinetics discussed in section 2.5. 
3.4.3 Circular dichroism spectroscopy 
Circular dichroism (CD) is a technique that measures the differential absorption of left- 
and right-handed circularly polarized light. This phenomenon only occurs for chiral 
molecules, which includes amino acids (except glycine), and thus peptides and 
proteins. In the context of biophysical studies, CD is most often used to study the 
secondary structure of proteins. An optical transition shift or split into multiple 
transitions occur when the amide chromophores of the polypeptide backbone are 
aligned in arrays, resulting in different characteristic spectra depending on the 
structural element. The three prototypical structural elements are α-helix, β-sheets and 
intrinsically disordered structures, all of which have distinct far-UV CD spectra (Figure 
10). The CD instrument typically gives a unit of degrees of ellipticity (θ), which, for 
proteins, is then converted into mean residue molar ellipticity. The degree of ellipticity 
per amino acid is reported through this conversion, which allows one to crudely 
compare the amount of secondary content between different proteins. Although this 
comparison becomes significantly unreliable when comparing proteins with mixed 
secondary structure. 
 
Figure 10 Schematic representation of the different characteristic CD spectra exhibited by α-helix (blue), β-sheet 
(red) and intrinsically disordered proteins (green). 
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3.5 Atomic force microscopy 
Atomic force microscopy makes use of a sharp probe that scans across the surface of 
the object of interest. The set-up includes a movable stage, a scanning head onto 
which the probe is mounted and a response detecting laser. The probe itself is attached 
to a cantilever where the opposite side of the probe is highly reflective. Due to the high 
sensitivity of the technique it is necessary to have a nearly atomically flat substrate, 
which most commonly, for biomolecules, is mica. This silicate mineral gives an ultraflat 
negatively charged hydrophilic surface as it is cleaved, that readily adsorbs proteins to 
the surface. As the probe scans across the surface, interactions between the outermost 
atoms of the tip of the probe and the object occur as they are brought into proximity of 
each other, which results in a deflection of the probe, that is then recorded by laser 
reflections from the probe to the detector. This allows the creation of topographical 
images (256). AFM can be used in different modes, with the most common one for 
static topographical imaging being intermittent contact (or tapping) mode. The 
intermittent contact mode works by vertical oscillation of the cantilever with a fixed 
amplitude. However, as the cantilever is brought into proximity of the object, the 
interacting forces between the tip and the object will cause a change to the oscillation 
amplitude, which through a feedback loop alters the vertical position of the stage to 
maintain the fixed amplitude and this generates a topographic image of the sample. 
This technique can allow sub-nanometer vertical resolution, and approximately 1 nm 
lateral resolution, and is a common technique for imaging amyloid fibrils (257).  
3.6 Electron microscopy 
Optical and electron microscopes are similar in many ways. Both light and electrons 
can be described as particles, and in terms of wavelengths. While typical optical 
microscopes utilize the visible spectrum that has wavelengths of 400-700 nm, with a 
diffraction limit of about 150 nm, electron microscopes use electrons that have 
wavelengths in the range of 0.001 and 0.01 nm and are capable of separating two 
points with about 0.05 nm distance (258, 259). Benefits of electron microscopes over 
light microscopes include higher resolution, higher magnification, greater depth of field 
and versatility. However, disadvantages with electron microscopes exist as well. They 
are expensive to build and maintain, and as electrons are far more scattered by air 
than light, where they would barely penetrate a few mm at atmospheric pressure, the 
electron path has to be in a vacuum. This text will focus on the transmission electron 
microscope, although much is shared with the scanning electron microscope. The 
electron microscope has several parts, where the “illumination” source is an electron 
gun, which emits electrons that passes through two or more electromagnetic 
condenser lenses. These lenses fulfill much the same function as an optic condenser 
lens, by focusing the electrons onto the sample. Below the condensers is the sample 
chamber, where the sample scatters electrons depending on thickness and material 
(less than 100 nm), and the electrons that exit pass the objective and intermediate 
lenses. The image is finally created as the electrons hit the imaging device, often a 
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phosphor screen (258). This technique can be used to image amyloid fibrils, where 
heavy metal salts are adsorbed onto the fibrils, whereafter an electron image can be 
generated due to differential electron scattering as a result of the mass-thickness 
difference between the fibrils and the stain (260). Additionally, specific protein species 
can be detected through the use of immunogold staining, where primary antibodies 
recognize the protein, after which secondary antibodies with attached colloidal gold 
particles recognize the primary antibodies. The gold then scatters electrons, allowing 
one to detect the antigen binding location. 
3.7 Surface plasmon resonance 
A highly sensitive technique capable of quantitively detecting the dynamic binding of 
biomolecules is surface plasmon resonance (SPR). SPR can provide binding affinity, 
specificity and kinetics, and it does so by detecting changes on the surface upon 
binding. Essentially, the SPR detection system consists of a polarized and 
monochromatic light source, a prism with a thin metal film at the base, and a detector. 
A reaction flow-chamber is present on the other side, where biomolecules of interest 
can be immobilized. The incident light at the base of the prism is directed at a specific 
resonance angle, which results in excitation of surface plasmons by some photons, 
whereas the rest are reflected to the detector. An evanescent electromagnetic field is 
created at the metal-liquid interface as the surface plasmons become excited, which 
decays exponentially into the interfacing medium where immobilized biomolecules 
reside. The resonance angle depends on the refractive index, which in turn is 
dependent on the evanescent wave. As biomolecules are immobilized, or bind to 
immobilized biomolecules, the evanescent wave is affected, resulting in a changed 
refractive index and resonance angle, thus affecting the amount of photons reflected 
to the detector (261). In most instruments the change in resonance angle is converted 
into “response units” which is linearly proportional to the bound mass on the surface, 
thus allowing real-time observation of the binding and dissociation processes. This can 
be done either by analyzing the time dependent traces of the binding to obtain the rate 
constants, or by using the equilibrium binding data at different concentrations of the 








4. Original work 
This section of the thesis aims to summarize and discuss the work performed in the 
research papers; wherein further details can be gathered. The section will start with 
the explored amyloid fibril formation mechanism of β-PV, a study that was then 
expanded to investigate possible consequences of specific cell conditions, i.e 
macromolecular crowding and stabilizing osmolytes, on protein misfolding and amyloid 
fibril formation (paper I-II). Subsequently, the interaction of β-PV with αS will be 
discussed (paper III), followed by the interaction of αS with the endogenous copper 
chaperone, Atox1 (paper IV).  
4.1 Amyloid fibril formation of fish β-parvalbumin 
Amyloid fibril formation of fish β-PV was first described in 2015, when it was found that 
low pH or removal of Ca2+ resulted in protein aggregation (151). As it was later 
observed that the fibrillization at pH 7.5 appeared to require the single conserved 
cysteine (177), it was thus an intriguing system to explore mechanistically, to expand 
the current knowledge of oxidation induced cross-linking and subsequent aggregation 
of folded proteins (paper I). Furthermore, as multimerization is favored by 
macromolecular crowding, as well as the dehydration of hydrophobic residues by 
stabilizing osmolytes, the effect of these conditions on the aggregation of a folded 
protein whose amyloid fibril formation is catalyzed by an initial covalent dimerization 
step appeared as an interesting venue to expand on (paper II).  
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4.1.1 Disulfide-mediated nucleation and monomer recruitment by 
fibrils 
Oxidative stress is a pathological hallmark of a number of amyloidoses, including 
Alzheimer’s disease, PD and diabetes type 2 (262, 263). Oxidative stress can in turn 
modify proteins, with one possible outcome being different types of intra- and 
intermolecular cross-links, e.g. cystine and dityrosine (264). In fact, dityrosine cross-
linking has been observed in both amyloid-β plaques (265) and Lewy bodies (218) in 
vivo, as well as implicated in facilitating dimerization and aggregation of amyloid-β and 
αS (265, 266). Additionally, the highly cross-linking prone residue cysteine is present 
in several amyloidogenic proteins, although current studies are limited in regard to the 
impact of intermolecular disulfide bonds in amyloidoses. Apo-SOD1 has been shown 
to become amyloidogenic upon reduction of the homo-dimeric disulfide bond at pH 7.4, 
with the reduced variant being capable of recruiting disulfide-intact apo-SOD1. 
Although, the reduced residues were implied to be necessary for initiating nucleation 
by subsequent intermolecular disulfide-bond formation (267). Transthyretin, which has 
two cysteine residues, has also been investigated, where disulfide bridges in the 
Tyr114Cys variant were observed to impaired the amyloid fibril formation (268), 
whereas the Cys10Ala/Tyr114Cys mutant could proceed to protofibrils (269). Lastly, 
the human tumor suppressor protein p16INK4A, which has one cysteine residue, was 
found to form amyloid fibrils upon addition of excess oxidizing agents and agitation. In 
this case, the disulfide-bridged dimers could form amyloid fibrils that were destabilized 
and disassembled upon reduction of the disulfide-bridge (270). Synthetic variants of 
amyloidogenic proteins that do not have cysteine residues have also been created, 
and it has been observed that the amyloid-β Ser26Cys mutant aggregated more rapidly 
than the wild-type form, albeit halted at the protofibrillary stage (271). A cysteine 
introduced αS mutant showed increased or reduced aggregation depending on 
whether the residue was introduced at the C- or N-terminal (272). Lastly, recombinant 
introduction of Tyr39Cys or Tyr125Cys αS mutants to cells displayed increased 
intracellular triton X-100 insoluble inclusions, which was further exacerbated by 
oxidative stress (273). The modulation of amyloid fibril formation by intermolecular 
disulfide bonds has varying effects depending on the protein and the location of the 
cross-linking cysteine, but current knowledge is lacking in this area. A perfect protein 
model for further expanding the understanding of this phenomenon is thus β-PV, as it 
is highly stable and monomeric in its holo-form, and contains a single cysteine which 
is thought to be important in amyloid fibril formation as β-PV transitions to its apo-form; 
which in turn can be easily controlled and triggered. As mammalian β-PV transitions to 
its apo-form, the buried cysteine side-chain becomes exposed to the environment 
(158, 160). Only the holo-form of fish β-PV has been solved by NMR, but it agrees well 
with the high-resolution structures of human holo-β-PV (Figure 11) (274). 
To investigate the mechanism by which β-PV forms amyloid fibrils, aggregation 
of β-PV at different concentrations was monitored. From these data it could be 
observed that the fluorescence half-time (i.e. the point at which fibril mass has reached 
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50 % of its final mass) against protein concentration displayed a linear relationship on 
a double- logarithmic plot (Figure 12A). This suggests that the main mechanism does 
not change over the assayed range. In contrast, a negative curvature would suggest 
competition between processes and changes in the dominant process with 
concentration, whereas a positive curvature (i.e. flattening of the curve at higher 
concentrations) would suggest a saturation effect (182). Globally fitting mathematical 
models of amyloid fibril formation to the data through the use of the web-based Amylofit 
program (182) revealed that primary nucleation and elongation steps fitted well. To 
verify that secondary processes are not involved, non-sonicated fibrils were added to 
monomeric β-PV, and were found to be incapable of surface catalyzing nuclei 
formation, thus agreeing with the mathematical models (Figure 12B). Additionally, 
fibrils are incapable of recruiting holo-β-PV. To verify that the fibrils are elongation 
competent, as the model suggests, sonicated pre-formed fibrils were added, and 
elongation could be observed (Figure 12C).  
To investigate whether the formed fibrils contain monomers, dimers, or both, 
they were sedimented by ultracentrifugation (100 000 g) and disaggregated by 
Figure 11 NMR solution structures of apo- and Ca2+-β-PV of G. morhua (PDB: 2MBX), H. sapiens (PDB: 1TTX) 
and rat (PDB: 2NLN), with the green spheres representing  Ca2+. Cysteine is visualized as a stick representation 
and can be observed to be buried in the holo-form, whereas it is exposed in the apo-form. 
Figure 12 ThT aggregation kinetics of apo-β-PV under quiescent conditions at 37 ˚C (150 mM NaCl, 1 mM CaCl2, 
5 mM EDTA and 25 mM Tris-HCl, pH 7.4). (A) Double-logarithmic plot of fluorescence half-time against monomer 
apo-β-PV concentrations. (B) Aggregation kinetics of 50 μM apo- and holo-β-PV in the presence of 0 and 5 % 




hexafluoroisopropanol (HFIP). The disaggregated β-PV was then run on a non-
reducing SDS-PAGE, which revealed an incorporation of ~40 % dimers (Figure 13B). 
As the dimers are the likely result of cysteine oxidation, the effect of oxidizing and 
reducing conditions on the apo-β-PV aggregation kinetics was investigated, and it 
could be observed that H2O2 accelerates the aggregation, whereas DTT retards it 
(Figure 13A). Furthermore, performing a non-reducing SDS-PAGE on the 
disaggregated fibrils after either conditions displayed that H2O2 and DTT result in an 
increased and decreased dimer content, respectively (Figure 13B). 
To gain a deeper understanding of the dimer involvement in amyloid fibril 
formation of apo-β-PV, efforts to isolate them were undertaken. By incubating β-PV 
with increasing amounts of H2O2 at 4 ˚C, it could be observed that dimers formed in an 
H2O2-concentration dependent manner for apo-β-PV, but not in the case of holo-β-PV 
(Figure 14A). This further substantiates the notion that the cysteine is protected in the 
holo-form for fish β-PV, as it is for mammalian β-PV (158, 160, 274). The formed dimers 
could then be isolated from the monomers by size exclusion chromatography, even 
remaining in a stable non-aggregated state in the holo-dimer form. As they can be 
completely reduced to monomeric forms by DTT, it indicates that they are connected 
by a cystine (paper I). Interestingly, investigating the secondary structure of the β-PV 
dimers by CD, it becomes apparent that they retain a large degree of the native 
monomeric structure, and are capable of transitioning between the characteristic CD 
spectra of apo- and holo-β-PV (Figure 14BC). 
After successful isolation of β-PV dimers, several kinetic aggregation assays 
were performed. Aggregation experiments over a concentration range of apo-β-PV 
dimers (4-15 μM monomer equivalents) showed a concentration dependency with a 
linear double-logarithmic half-time vs concentration plot, akin to the monomers (Figure 
15A). Mathematical modeling with Amylofit could fit the nucleation-elongation model 
for the kinetic profiles of apo-β-PV dimers as well, although this time with a 20-fold  
Figure 13 (A) ThT aggregation kinetics of apo-β-PV in the presence of 100 μM H2O2 or DTT, under quiescent 
conditions at 37 C˚ with 150 mM NaCl, 1 mM CaCl2, 5 mM EDTA and 25 mM Tris-HCl (pH 7.4). (B) SDS-PAGE 
analysis of disaggregated apo-β-PV fibrils after incubation in (A). 
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increased convoluted rate constant compared to the monomers (in monomer 
equivalents, paper I). In addition, Ca2+-β-PV dimers did not form amyloid fibrils (paper 
I). To investigate whether the apo-β-PV dimers were capable of recruiting monomers, 
increasing amounts of dimers were added to monomers and the kinetics were followed. 
As can be seen, an increasing apo-β-PV dimer concentration above 1 % results in a 
concentration dependent acceleration of the monomeric aggregation rate, shortening 
the half-time from 21.7 ± 1.5 h to 13.6 ± 1.7 h for 5 % dimers (Figure 15B). Together 
with the fact that the fibrils are capable of recruiting monomers for elongation (Figure 
12C), this shows that the dimers can act as nuclei alone, or possibly together with 
monomers if they are present, and the formed nuclei may then further recruit 
monomeric apo-β-PV, thus creating heterogeneous fibrils. 
Investigating whether there is any detectable morphological difference by AFM 
showed that fibrils formed from monomer, monomers accelerated by dimers, and 
dimeric apo-β-PV starting material all shared the same curvilinear appearance, 
clustering preference and fibril heights (Figure 16A-C). Furthermore, analyzing the 
fibrils from both monomeric and dimeric starting material by CD displays that they 
Figure 14 (A) SDS-PAGE of 50 μM β-PV incubated in the presence of 0-100 μM H2O2 over 20 h at 4 ˚C, in 1 mM 
CaCl2, 5 mM EDTA (for apo) and 25 mM Tris-HCl (pH 8.22). (B and C) CD spectra of 15 μM β-PV (monomer 
equivalent) of monomers (blue) and dimers (red) at 21 C˚ in 1 mM CaCl2, 5 mM EDTA (for apo) in Tris-HCl (pH 
7.8) in Ca2+- (B) or apo-β-PV state (C). 
Figure 15 ThT assay of apo-β-PV under quiescent conditions at 37 ˚C (150 mM NaCl, 1 mM CaCl2, 5 mM EDTA 
and 25 mM Tris-HCl, pH 7.4). (A) Double-logarithmic plot of fluorescence half-time against apo-β-PV 




share an equal proportion of secondary structure content (Figure 16D). This thus 
further supports the notion that apo-β-PV fibrils share the same conformation 
regardless of monomeric or dimeric origin.  
As discussed in section 2.4, fish β-PV and mammalian β-PV appear to be more 
different than how it has been described in the literature. The major structural 
reorganization displayed by mammalian β-PV, as it transitions from holo- to apo-form, 
occurs in the Ca2+ specific CD-domain (159, 160). However, fish β-PV has two 
Ca2+/Mg2+ mixed sites, i.e. the CD-domain is a mixed binding site (163), and a fast and 
dramatic structural change is typically a characteristic of Ca2+ specific signal 
transduction proteins (159). This thus raises the question whether fish β-PV undergoes 
the same structural reorganization as mammalian β-PV, and if Mg2+ is capable of 
inducing the change as well. Several experiments were performed to probe this, albeit 
indirectly. ThT aggregation assay displayed that 2 mM MgCl2 was capable of 
completely preventing β-PV from proceeding to amyloid fibrils (lower concentration 
was not tested) (Figure 17A). Furthermore, upon exposure of Mg2+-β-PV to H2O2, it 
could be observed by SDS-PAGE that, in similarity to Ca2+-β-PV, dimers did not form, 
whereas apo-β-PV readily formed dimers (Figure 17B). Ellman’s assay, which 
quantifies sulfhydryl groups, was also employed, and showed that while apo-β-PV had 
instantaneous reaction of all its thiols, the thiols in Ca2+- and Mg2+-β-PV reacted far 
 
Figure 16 (A-C) AFM images of apo-β-PV fibrils created from monomeric (A), monomers accelerated by dimers 
(B) and dimeric (C) starting material. (D) CD spectra of apo-β-PV fibrils formed from monomeric (blue) and 
dimeric (red) starting material, signal matched at 222 nm (unknown concentration). 
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slower, and did so with an identical response to Ellman’s reagent regardless of the ion 
(Figure 17C). These data thus suggest that, similar to mammalian β-PV, fish β-PV also 
undergoes structural reorganization upon loss of ligands, resulting in an exposed 
cysteine. Whether the reorganization is as significant as for mammalian β-PV remains 
to be answered. 
Taken together with the study performed by Castellanos et al. (177), which 
showed that substituting the conserved cysteine with a serine results in ThT reactive 
non-fibrillary aggregates with incomplete β-sheet transition, our results suggest that 
the cystine formation is required for the formation of initial nuclei and subsequent fibril 
growth through templating of either monomers and/or dimers. However, while 
enhanced ThT fluorescence does not necessitate an amyloid fibril conformation, it 
cannot be excluded that the non-fibrillary aggregates displayed by Castellanos et al. 
(177) do not contain partial regions within β-PV that adopt the amyloid conformation. 
Although that is a phenomenon that is more prevalent with larger proteins (17). 
These results are similar to those obtained for the protein p16INK4A, which also 
requires an intermolecular disulfide-bond between the sole cysteine of two protein to 
form amyloid fibrils. However, p16INK4A fibrils are also stabilized by this bond and 
incapable of recruiting monomers, as reduction of the bond results in disaggregation 
of the fibrils, and formation of the fibrils requires added oxidizing agents and agitation 
(270). Fibril formation by apo-β-PV, on the other hand, requires neither oxidizing 
agents nor agitation. Instead, spontaneous disulfide bonds may form in vitro in reaction 
with dissolved O2 (275-277), which may facilitate the apo-β-PV fibrillization (Figure 18). 
 Interestingly, unlike the fish orthologue, mammalian β-PV is remarkably stable 
from forming cystines in its apo-form, despite an exposed cysteine thiol. Mammalian 
apo-β-PV does not form dimers after incubation at room temperature for 30 hours 
(278), and it remains in a monomeric state at concentrations as high as 4 mM (160). 
Fish β-PV, on the other hand, forms dimers detectable by SDS-PAGE after 20 hours 
at 4 ˚C (Figure 14A). If one may speculate, there may be several reasons for this 
difference. Lower vertebrate β-PV exists intracellularly in the muscles, and cycle 
between Ca2+- and Mg2+-bound forms (173), and should thus never be in an  
Figure 17 (A) ThT aggregation kinetics of apo- and  Mg2+-β-PV under quiescent conditions at 37 ˚C (150 mM 
NaCl, 2 mM MgCl2, 25 mM Tris-HCl, pH 7.4, and 10 mM EDTA in the apo-β-PV sample). (B) SDS-PAGE of 50 
μM β-PV incubated at under quiescent conditions at room temperature for 20 hours in 25 mM Tris-HCl (pH 7.8) 
and 50 μM H2O2. (C) Ellman’s assay of 35 μM β-PV in 25 mM Tris-HCl, pH 7.8, 5 mM EDTA (for apo) incubated 
over 200 minutes at room temperature (duplicate). 
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apo-state in vivo. Instead, the structural reorganization observed may be a feature to 
modulate the Ca2+- and Mg2+ binding affinities, by imparting a penalty upon binding, 
thus lowering the affinity (160, 176). Mammalian β-PV, on the other hand, displays 
different tissue expression patterns. It is, for example, secreted by macrophages during 
intraocular inflammation (169), and activated macrophages reside in heavily oxidizing 
environments (e.g. inflammation). This may require mammalian β-PV to possess a 
stronger ligand independent stabilization of the native structure in this extracellular 
environment, possibly with additional features such as local charge repulsion 
preventing the thiols from approaching each other. In addition, G. morhua β-PV is not 
designed for the high temperatures of mammals, where 37 ˚C might thermally 
destabilize the protein structure. Combined with loss of ligands and thermal 
destabilization, a local unfolding and thus exposure of adhesive, hydrophobic, residues 
of G. morhua β-PV might occur, that in turn may bring the thiols into vicinity of each 
other and thus facilitate disulfide-bond formation. The formed dimer may then result in 
further destabilization and local unfolding, as well as increasing the chance of collision 
between two segments possessing, at the same time, the conformational compatibility 
for forming the initial intermolecular beta-sheets. 
Another intriguing question arises as to the purpose of the metabolically 
expensive cysteine (279) that has been conserved between all the lower vertebrates. 
One possible answer might be that β-PV acts as a redox sensor, as cysteine is known 
to act as a redox sensor in vivo. The way cysteine does so is through oxidation to 
sulfenic or sulfinic acid, that in turn can be recognized by the cell (280). Muscles, in 
turn, produce a lot of reactive oxygen species during contraction that, at too high levels, 
result in contractile dysfunction and muscle fatigue (281). The Ellman’s assay showed 
that while the thiol was more protected in Ca2+ and Mg2+ bound β-PV, it was, however, 
not inaccessible (Figure 17C). The levels of the muscle reactive oxygen species might 
thus be sensed by the abundantly expressed β-PV, resulting in adaptation of the 
antioxidant defenses. A similar function might also hold true for mammalian β-PV, 
where it might have a function in sensing the oxidative environment during e.g. 
inflammation.  
Figure 18 Proposed dominant apo-β-PV amyloid fibril formation mechanism, which is initially triggered by 
conformational change concomitant with cysteine exposure as the ligands release (i.e. Ca2+ and Mg2+) from the 
holo-form (MHOLO). The monomer in its apo-form (MAPO) then, in reaction with O2, forms a disulfide bond with 
another monomer, thus creating covalent apo-dimers (DSS, APO). These dimers may then proceed to nuclei and 
amyloid fibrils that can be elongated by both monomeric and dimeric apo-β-PV. 
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4.1.2 Macromolecular crowding and stabilizing osmolytes accelerate 
aggregation of apo-β-parvalbumin 
Another interesting aspect of amyloid fibril formation in vivo is how it is modulated by 
the steric effect of macromolecular crowding. As described in section 2.5.2, folded 
proteins in their native state become stabilized by macromolecular crowding (225, 
227), but when they are partially destabilized, i.e. low pH (225, 228) or in the absence 
of a crucial ligand (229), macromolecular crowding might accelerate amyloid fibril 
formation. The effect of macromolecular crowding is thus interesting from the 
perspective of β-PV. As β-PV releases Ca2+ its conformation becomes expanded, 
although it still retains an α-helical fold. Thus, macromolecular crowding could, on one 
hand, potentially stabilize apo-β-PV by reducing its conformational space (219). On the 
other hand, as dimerization facilitates amyloid fibril formation, it is also possible that 
macromolecular crowding will promote multimerization of apo-β-PV, that can lead to 
amyloid fibril formation. Furthermore, if the intermediate species towards nuclei result 
in expanded conformational states, they may be prevented from forming amyloid fibrils, 
instead resulting in e.g. native-like aggregates. In a similar vein, and as discussed in 
2.5.3, protective osmolytes might also stabilize the protein native monomeric state, or 
facilitate multimerization, due to osmophobic effect and unfavorable interaction with 
protein backbone, which in turn might either prevent or facilitate amyloid fibril formation, 
respectively. 
The ThT aggregation assay was employed to monitor the amyloid fibril 
formation of apo-β-PV in the presence of the different macromolecular crowding agents 
and stabilizing osmolytes. Ficoll 70 was primarily used as a macromolecular crowding 
agent, as it is generally considered inert with little or no protein interactions (282-284). 
The aggregation rate of apo-β-PV in presence of 100 and 200 mg/ml Ficoll 70 
displayed a significant acceleration compared to incubation in buffer alone, with a 
reduced half-time from 32 ± 3 h to 11 ± 1 h (100 mg/ml) and 4.5 ± 0.2 h (200 mg/ml), 
and drastically shortened lag time (Figure 19A). The increase in aggregation rate by 
Ficoll 70 is quite substantial, as 30 μM apo-β-PV in 100 mg/ml (6.5 % excluded volume) 
Ficoll 70 results in an aggregation half-time of ~10.5 h, which is what would be 
expected from ~100 μM β-PV (Figure 12A). AFM was utilized to visualize the sample 
at the plateau of the fluorescence ThT intensity, revealing fibrils that appear similar for 
both buffer and macromolecular crowding conditions (paper II). The data suggest that 
macromolecular crowding does not stabilize the monomeric β-PV state, thus allowing 
nuclei formation, and drastically accelerates either nucleation, elongation or both. To 
probe the apo-β-PV conformation in macromolecular crowding conditions, far-UV CD 
was used at 50 mg/ml Ficoll 70, as higher Ficoll 70 concentration induced aggregation 
at a too rapid pace. Since the holo-state of β-PV is a more compact state (177), one 
might speculate that any compaction and stabilization would result in a CD spectrum 
similar to that of the holo-state. However, at 50 mg/ml Ficoll 70, no immediate 
secondary structure content difference could be observed (Figure 19B). To investigate 
whether the effect can be replicated by another crowding agent, PEG 35,000 was used, 
which again resulted in an accelerated aggregation (Figure 19C).  
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Sucrose and glycerol were then used to test the effect of stabilizing osmolytes. The 
results showed that both sucrose and glycerol accelerated apo-β-PV amyloid fibril 
formation in a concentration dependent manner, reducing the lag time (Figure 19D). 
The overall aggregation rate was not promoted as strongly as in the case of Ficoll 70 
when considering the concentration (weight/volume) of the agent, where 380 mg/ml 
sucrose reduced the half-time by a factor of two, whereas 200 mg/ml Ficoll 70 reduced 
the half-time by a factor of seven (Figure 19AD). AFM shows the same curvilinear fibrils 
are formed in sucrose and glycerol as for buffer (paper II).  
To delineate whether the elongation rate is affected, seeding experiments (7.5 
μM sonicated pre-formed fibrils) were performed at Ficoll 70 and sucrose 
concentrations that still allowed for a lag-phase, i.e. 50 and 190 mg/ml, respectively. 
The initial linear slope of fibril mass increase corresponding solely to elongation was 
then investigated, and it could be seen that whereas Ficoll 70 accelerates the 
elongation rate of apo-β-PV, sucrose retards (Figure 21). Acceleration of the fibril 
elongation rate appears to be a generic effect of macromolecular crowding by high 
weight polymers (e.g. dextran 200 kDa) on IDPs and destabilized globular proteins, 
and was associated with the changes in volume available to the reactants and products 
(285). The stabilizing osmolyte, sucrose, instead has the opposite effect, delaying the 
fibril elongation rate. This might be due to the polymerization reaction requiring an 
expanded conformational transition of β-PV as it restructures from α-helices to β-
sheets. As such, sucrose might prevent the transition due to the osmophobic effect, 
which is in line with previous results showing that glucose prevents globular proteins 
 
Figure 19 ThT aggregation kinetics of 30 μM apo-β-PV under quiescent conditions at 37 ˚C (150 mM NaCl, 1 
mM CaCl2, 5 mM EDTA and 25 mM Tris-HCl, pH 7.4) with 0-200 mg/ml Ficoll 70 (A), 0-40 mg/ml PEG 35,000 
(C) or 0-390 mg/ml sucrose (blue) or 0-566 mg/ml glycerol (red) (D). (B) CD spectra of 15 μM apo-β-PV at 21 C˚ 
in 96 μM CaCl2, 1 mM EDTA, 10 mM Tris-HCl (pH 7.8) with (red) or without (blue) 50 mg/ml Ficoll 70. 
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that retain a significant degree of their structure from polymerizing the fibril (285). 
However, there might also be increased diffusion limitation as a result of increased 
viscosity, thus retarding elongation, which cannot be delineated from these data (286). 
Furthermore, as sucrose reduces the elongation rate, while still accelerating the overall 
aggregation, it appears that stabilizing osmolytes facilitate nucleation of apo-β-PV. 
Both macromolecular crowding conditions and presence of stabilizing 
osmolytes accelerate the overall aggregation of β-PV. Macromolecular crowding 
appears to do so sterically, by reducing occupied volume through multimer association, 
thus maximizing system entropy. While it can be observed that the excluded volume 
effect accelerates elongation, the data do not confirm whether nucleation is 
accelerated as well, as fibrils may have already formed in the lag phase. Stabilizing 
osmolytes, on the other hand, might accelerate aggregation through the osmophobic 
effect, thus facilitating multimerization in order to reduce the solvent accessible surface 
area and in turn facilitate disulfide bonds and subsequently nuclei formation.  
  
Figure 20 (A) ThT aggregation kinetics of 30 μM apo-β-PV under quiescent conditions at 37 ˚C (150 mM NaCl, 
1 mM CaCl2, 5 mM EDTA and 25 mM Tris-HCl, pH 7.4) with or without 7.5 μM sonicated pre-formed fibrils, either 
in buffer, 50 mg/ml Ficoll 70 or 390 mg/ml sucrose. (B) Elongation rate of (A) during the first 2.3 hours. 
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4.2 Effect of fish β-parvalbumin amyloid fibrils on α-
synuclein aggregation 
As mentioned in section 2.3, diet is one implicated modulator of PD initiation; where 
e.g. the Mediterranean diet has been correlated with a reduced PD incidence (287). 
Fish in particular is generally considered beneficial against several age-related 
diseases, including dementia and Alzheimer’s disease (288-290), which is typically 
assumed to be due to ω-3 fatty acids (291). However, direct evidence of such an effect 
by ω-3 is lacking (292), possibly due to the fact that the triggering event is thought to 
occur decades before clinical symptoms, thus making such studies difficult endeavors 
(20, 63). Nevertheless, there are multiple components to fish, with one being fish β-
PV, which is expressed at a concentration as high as 0.2 g / 100 g muscle tissue  
depending on the fish species (293). Additionally, while most dietary proteins are 
proteolytically degraded as to recycle and utilize the individual building blocks (294), 
β-PV instead forms amyloid fibrils that confer a resistance against proteases (151). In 
fact, following a meal of fish, β-PV epitopes can be recognized in the blood (178), 
implying not only retained sequence and/or structure, but also transcellular transport. 
As αS appears to be a pleiotropic protein (20, 99, 100) with a wide tissue expression 
(98, 101-103), including in the gastric and enteric environment, e.g. enteroendocrine 
cells that sample the intestinal lumen (103), it is thus interesting to investigate whether 
β-PV interacts with αS.  
To investigate whether β-PV is capable of modulating the amyloid fibril 
formation of αS, the ThT assay was employed. As can be observed, while the addition 
of 280 μM non-aggregating Ca2+-β-PV to 70 μM αS has no effects on αS kinetics 
(Figure 21A), apo-β-PV appears to be capable of completely inhibiting αS aggregation, 
as the resulting kinetics in the samples with both proteins show identical aggregation 
curves to that of apo-β-PV alone, rather than co-aggregation of both (Figure 21A). As 
the apo-β-PV kinetics are completely unaffected by αS, this suggests that it is not the 
monomers but rather the formed fibrils that prevent αS from aggregating. To test 
whether this is the case, 280 μM pre-formed fibrils of apo-β-PV were added to 70 μM 
αS. Apo-β-PV fibrils also displayed an inhibitory behavior on αS aggregation (Figure 
21B). Since amyloid fibril formation can be inhibited at many different stages, the 
question arises as to whether the apo-β-PV fibrils interact with monomeric or 
assembled pre-fibrillar αS species. Since αS does not display secondary nucleation at 
pH 7.4, and fibril growth occurs by monomer addition (295), one might expect all 
observed non-β-PV kinetics to be due to elongation. To probe this, 1 and 5 % pre-
formed αS fibrils were added to a solution containing 280 μM apo-β-PV and 70 μM αS.  
Interestingly, the observed kinetics are identical to those of apo-β-PV monomers for 
longer than 20-30 hours, followed by an increase of ThT fluorescence intensity, which 
is attributed to αS aggregation (Figure 21C). These results indicate that apo-β-PV fibrils 
are capable of slowing down the elongation rate of αS, likely by sequestering 
monomers from the solution. However, the aggregation of αS after about 25 h is difficult 
to explain, as one might expect that any elongation should occur at a constant rate due 
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to an equilibrium of monomeric αS release from the apo-β-PV fibrils. In addition, adding 
1 mM Ca2+ to αS inhibited by β-PV fibrils appears to induce αS aggregation (paper III). 
This effect might be due to direct interaction of Ca2+ with either β-PV or αS. The amyloid 
fibril core of β-PV does not incorporate the Ca2+ binding loops (151, 177), and if αS 
interacts with these, Ca2+ might interfere. On the other hand, direct interaction of Ca2+ 
with αS in the C-terminal and part of the NAC-region has been shown (110), and should 
αS interact with β-PV fibrils through these domains, Ca2+ might shift the equilibrium 
towards released αS. 
To investigate whether αS remains in a soluble non-fibrillar state when 
incubated together with apo-β-PV (Figure 21D), as the ThT experiments suggest, as 
well as whether the aggregation end-product morphology supports the ThT 
experiments, SDS-PAGE and AFM were used. SDS-PAGE shows that while soluble 
αS is clearly diminished in samples without apo-β-PV, it remains in a soluble form to a 
far greater degree in the presence of apo-β-PV (Figure 21D). 
To verify that αS binds the β-PV fibrils, transmission electron microscopy 
together with immunogold staining was used, by employing non-conformationally 
specific αS reactive antibodies. From these images it can clearly be seen that while αS 
Figure 21 ThT aggregation kinetics of 70 μM αS and 280 μM apo-β-PV under agitation with 2 mm beads at 37 
˚C (150 mM NaCl, 1 mM CaCl2, 5 mM EDTA (for apo) and 25 mM Tris-HCl, pH 7.4). Pre-formed fibrils (PFF) of 
280 μM apo-β-PV in (B) and αS PFF in (C). (D) SDS-PAGE analysis after aggregation in (A). 
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fibrils are readily recognized by the antibodies, the β-PV fibrils are not. However, in the 
samples where αS has been incubated together with apo-β-PV, epitope reactivity can 
be observed for fibrils displaying β-PV morphology (Figure 22). 
These results show that β-PV fibrils are capable of inhibiting αS amyloid fibril 
formation, likely involving monomeric αS binding to β-PV fibrils, thus sequestering αS. 
Although, the data do not fully exclude potential interaction with oligomeric αS, where 
the interaction could e.g. disassemble the oligomeric species. The binding location of 
αS is likely the surface of the β-PV fibrils, as the kinetics of the latter are unaffected by 
the presence of the former. From a physiological standpoint, considering the wide 
tissue expression of αS, including the gastrointestinal system (98, 101-103) where 
misfolded αS has been found (21, 22), as well as the apparent prevalence of an enteric 
origin in PD (18-20), β-PV would not be required to cross the blood-brain barrier for 
any potential interaction with αS. In addition, since there are indications that β-PV is 
capable of transcellular transport (178), β-PV might instead act directly in the gut, 
where PD triggering events might occur, thus preventing misfolding of αS. However, 
this is purely speculative at this point, as these findings are in a highly simplified in vitro 
system, and must thus be followed up with in vivo data prior to any conclusion. 
Nevertheless, the data are interesting from a purely molecular perspective, where the 
amyloid fibril of one protein appears to inhibit the amyloid fibril formation of another; in 
this case by αS binding to the surface of β-PV fibrils. 
  
Figure 22 Transmission electron microscopy images of fibrils incubated with non-conformationally specific anti-
αS antibodies and 2˚ antibodies coupled to gold nanoparticles. 
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4.3 Copper chaperone Atox1 blocks amyloid formation 
of α-synuclein 
Copper is one of the most abundant redox-active metal ions in humans, and is capable 
of generating reactive oxygen species through Fenton/Haber-Weiss reactions, that 
may then react with and damage lipids, proteins and DNA (296). Due to this toxic 
nature, virtually no free copper ions exists within the cell (297). Cells have instead 
developed sophisticated regulatory functions involved in the import, 
compartmentalization, transport and export of copper ions. After import of Cu+ by the 
transmembrane high-affinity copper uptake protein 1 (298), Cu+ is distributed to the 
copper chaperones antioxidant 1 copper chaperone (Atox1), cytochrome c oxidase 
copper chaperone and copper chaperone for superoxide dismutase (299). While αS is 
capable of binding copper ions, and has been implicated to both act as a ferrireductase 
(123) and depend on copper ions to modulate its cell membrane binding (122), the αS 
copper ion binding is relatively weak compared to the high affinity copper ion-binding 
proteins. Thus, any cytosolic copper ion-dependent activity would likely require the 
transfer of copper ions from another protein, if such a function exists. One such 
candidate could be the copper chaperone, Atox1.  
To probe the effect of Atox1 on αS aggregation, ThT assay with several 
conditions was undertaken. Addition of either equimolar apo- or Cu+-Atox1 to 70 μM 
αS results in a delayed aggregation (Figure 23A). To investigate whether αS remains 
in a soluble non-fibrillar state, SDS-PAGE was used to analyze the samples after the 
aggregation. As can be seen, while soluble αS in samples incubated with apo-Atox1 
was significantly reduced, samples with Cu+-Atox1 retained a large degree of soluble 
αS. Inhibition of αS aggregation by Cu+-Atox1 was further confirmed by SEC, where a 
significant fraction of monomeric αS was detected after the ThT assay (Figure 23B). 
To directly test whether Cu+-Atox1 is capable of binding αS, SPR was used, wherein 
biotinylated αS (maleimide conjugated through Ala107Cys mutation) was immobilized. 
Confirming the previous results, Cu+-Atox1 was found to bind αS in a concentration-
dependent manner, with a detected dissociation constant of ~5 μM, whereas no 
interaction with apo-Atox1 was detected (Figure 23C). To further probe the αS and 
Cu+-Atox1 interaction, a fresh mixture of the proteins was run through SEC. Cu+ bound 
to Atox1 results in absorption at 254 nm, and relating it to the 280 nm protein 
absorbance, relative Cu+ loading of Atox1 can be measured. While no complex was 
observed, it could be seen that Cu+ had been removed from Atox1, as the 254/280 nm 
ratio was reduced. As this ratio cannot be used to determine αS copper ion binding, 
the αS fraction was analyzed by inductively coupled plasma mass spectrometry for 
elemental analysis, which revealed elevated copper ion levels, suggesting transfer of 
copper from Atox1 to αS. 
In an attempt to probe the Atox1 binding site, the C-terminal truncated αS 
variant (αS 1-97) was incubated together with Cu+-Atox1. As the 1-97 αS amyloid fibril 
formation was inhibited by Cu+-Atox1 as well, the likely site of interaction is at the αS 
N-terminal, which is the location of the dominant copper ion-binding site (Figure 24A). 
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To test whether this effect is generic to copper chaperones, copper chaperone for 
superoxide dismutase was incubated together with αS, resulting in no observable 
effect on the aggregation of αS (Figure 24B). Thus, it would appear that Atox1 
specifically is capable of interacting with αS.  
As can be ascertained by these results, Cu+-Atox1 is capable of directly 
interacting with αS, thereby preventing its aggregation, whereas apo-Atox1 is not. The 
inhibition of 1-97 αS aggregation together with the copper ion transfer to αS indicates 
that a ternary complex is formed at the N-terminal of αS, bridged by Cu+, which was 
further confirmed by a subsequent study that showed that primarily the N-terminal, up 
to Gln24, is involved in the binding to Atox1 (300). Furthermore, as copper chaperone 
for superoxide dismutase was not capable of influencing the aggregation of αS, it would 
appear that the interaction is specific for Atox1, and not strictly facilitated by copper 
ions. A subsequent study showed that Cu+-Atox1 is also capable of inhibiting the 
aggregation of the physiologically relevant NAcαS, in addition to evidence suggesting 
Figure 23 (A) ThT aggregation kinetics of 70 μM αS and 70 μM Atox1 under agitation with 2 mm beads at 37 ˚C 
(150 mM NaCl and 50 mM Tris-HCl, pH 7.4). (B) Size exclusion chromatography (top) and SDS-PAGE analysis 
of soluble αS after (A). (C) Surface plasmon resonance analysis of Cu+-Atox1 binding to immobilized αS in 150 
mM NaCl and 10 mM HEPES pH 7.4 
 
Figure 24 ThT aggregation kinetics of 70 μM αS 1-97 and 70 μM Atox1 (A), and 70 μM αS and 70 μM copper 
loaded copper chaperone for superoxide dismutase under agitation with 2 mm beads at 37 ˚C (150 mM NaCl 
and 50 mM Tris-HCl, pH 7.4). 
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direct interaction between the two proteins in cells (300). However, the study showed 
by NMR that copper ion transfer did not occur. It is interesting to speculate whether 
Atox1 possesses a modulating effect on αS activity through direct interaction using a 
copper ion as a bridge, e.g. modulating αS vesicle/membrane binding, or even act as 












5. Concluding remarks 
Through medical advances, resulting in an ever-increasing life expectancy, an 
increasing number of debilitating diseases related to amyloid fibrils follows. The 
consequences of these diseases are major reductions to quality of life as well as heavy 
financial costs to both private and national economy. Despite tremendous efforts into 
understanding these diseases, no cure exists; in part due to the multifactorial nature of 
their origin and complex molecular mechanisms. The complexity of the diseases has 
hampered our attempts to understand them, and it is therefore important to build our 
knowledge to better understand how and through which processes these diseases 
arise, so that we may rationally devise preventative measures and treatments. The 
work in this thesis can be divided into two main amyloid fibril related themes: (1) 
providing a deeper fundamental knowledge of amyloid fibril formation mechanisms, 
which will help guide future research and treatment efforts; (2) investigate αS 
interaction partners in order to provide more specific and applicable directions on future 
PD treatments. 
The study of the amyloid fibril formation mechanism of the folded protein β-PV 
provided insights into the role of intermolecular interactions in protein aggregation (or 
fibrillization). The protein, upon losing its ligand Ca2+, dimerizes through the formation 
of disulfide bonds followed by subsequent nucleation and amyloid fibril elongation. 
These findings demonstrate a system that becomes amyloidogenic through a two-step 
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process and is initiated by the formation of a covalent bond known to stabilize protein 
structures. Ligand loss could occur in vivo for many proteins, as a result of e.g. metal 
ion dyshomeostasis, or other conditions where proteins are unable to access crucial 
interaction partners, thus leading to their destabilization and amyloid fibril formation. 
Such an event has been demonstrated for other proteins, as in the case of 
demetallation of the disease related superoxide dismutase, which results in protein 
aggregation. Furthermore, the subsequent cross-linking of the cysteine residues, thus 
forming the amyloidogenic β-PV dimers, could be mirrored in amyloidoses where 
oxidative stress is a common feature. Subsequent templating of monomers 
demonstrates a potentially cascading pathogenic event where the cells end up with 
toxic and difficult to clear aggregates. Additionally, the otherwise protective cellular 
conditions of macromolecular crowding and stabilizing osmolytes, that result in 
excluded volume and osmophobic effect, respectively, were shown to exacerbate the 
amyloid fibril formation of β-PV once it was triggered.  
Although amyloid fibrils are associated with diseases, they can also provide 
beneficial functions. β-PV in an amyloid fibril form was found to inhibit αS amyloid fibril 
formation, likely through sequestration onto the β-PV fibril surface. αS is expressed in 
the gastrointestinal tract, from which many PD incidences have been implicated to 
have originated. As β-PV forms amyloid fibrils in the gut, which then confers proteolytic 
protection, and tissue transit has been suggested, this fish protein could potentially be 
protective against PD. In fact, I set up a preliminary cell study using an enteroendocrine 
cell line and investigated potential uptake of fluorophore labeled β-PV by confocal 
microscopy. This study showed that while monomers were not taken up, fibrils were 
internalized at a very rapid rate, at lower concentrations than what the stomach 
concentration of β-PV would be after a meal of fish. 
The putative interaction between the endogenous copper chaperone Atox1 and 
αS was investigated, which showed that Cu+-Atox1, but not apo-Atox1, is capable of 
binding αS monomers and prevent their amyloid fibril formation. Additionally, it does 
not appear to be a generic copper chaperone effect, as copper chaperone for 
superoxide dismutase had no effect on the aggregation of αS. This interaction could 
be important in vivo, as it has been observed that the affected brain regions in PD have 
a reduced copper concentration. Such metal dyshomeostasis might then prevent the 
interaction of Cu+-Atox1 with αS, thus facilitating the progression of PD.  
The work in this thesis can be concluded as follows, based on the themes 
described in the first paragraph. (1) The combined effects of ligand loss and oxidative 
stress may induce amyloid fibril formation, and cellular environments, i.e. 
macromolecular crowding and stabilizing osmolytes are important, but often ignored, 
factors to consider. (2) β-PV is a potentially protective protein in fish that might prevent 
PD. However, physiological interaction still needs to be proven. First steps to elucidate 
this could be to investigate by which mechanism β-PV is taken up and whether it can 
gain access to the cytosol, if it is e.g. trapped in endosomes, in addition to studying a 
potential interaction between αS and β-PV in the cell. It is also an interesting general 
study for uptake mechanisms of amyloid fibrils, as it is unexpected that such large 
structures without endogenous origin would be taken up. The potential link between 
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αS copper binding capacity and the copper chaperone Atox1 should be followed up by 
expanding the study with more copper binding proteins to investigate whether more 
interactions exist. Research into understanding why the copper deficiency occurs is 
another important aspect, which may shed light on potential future therapies that may 
limit PD progression. For example, if the issue lies with faulty copper transporter 
expression or localization, one could work towards alleviating this. Alternatively, one 
could investigate delivery of copper, which is an approach that has indeed been 
initiated, with a synthetic compound known as CuATSM, and is currently undergoing 
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